

## Publications (updated to website 10/4/21, WL)

### Peer-Reviewed Publications

1. Patten PA, **Gray NS**, Yang PL, Marks CB, Wedemayer GJ, Boniface JJ, Stevens RC, Schultz PG. The immunological evolution of catalysis. *Science* 1996;271:1086-91.
2. Norman TC, **Gray NS**, Koh JT, Schultz PG. A structure-based approach to kinase inhibitors. *J Am Chem Soc* 1996;118:7430-1.
3. **Gray NS**, Kwon S, Schultz PG. Combinatorial synthesis of 2,9-substituted purines. *Tetrahedron Lett* 1997;38:1161-4.
4. Brooks EE, **Gray NS**, Joly A, Kerwar SS, Lum R, Mackman RL, Norman TC, Rosete J, Rowe M, Schow SR, Schultz PG, Wang X, Wick MM, Shiffman D. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. *J Biol Chem* 1997;272:29207-11.
5. **Gray NS**, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. *Science* 1998;281:533-8.
6. Rosania GR, Merlie J Jr, **Gray N**, Chang YT, Schultz PG, Heald R. A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using *Xenopus* egg extracts. *Proc Natl Acad Sci U S A* 1999;96:4797-802.
7. Chang YT, **Gray NS**, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. *Chem Biol* 1999;6:361-75.
8. Armstrong JI, Portley AR, Chang YT, Nierengarten DM, Cook BN, Bowman KG, Bishop A, **Gray NS**, Shokat KM, Schultz PG, Bertozzi CR. Discovery of Carbohydrate Sulfotransferase Inhibitors from a Kinase-Directed Library. *Angew Chem Int Ed Engl* 2000;39:1303-6.
9. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, **Gray NS**, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM. A chemical switch for inhibitor-sensitive alleles of any protein kinase. *Nature* 2000;407:395-401.
10. Knockaert M, **Gray N**, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. *Chem Biol* 2000;7:411-22.
11. Ding S, **Gray NS**, Ding Q, Schultz PG. A concise and traceless linker strategy toward combinatorial libraries of 2,6,9-substituted purines. *J Org Chem* 2001;66:8273-6.

12. Lin Q, Jiang F, Schultz PG, **Gray NS**. Design of allele-specific protein methyltransferase inhibitors. *J Am Chem Soc* 2001;123:11608-13.
13. Verdugo DE, Cancilla MT, Ge X, **Gray NS**, Chang YT, Schultz PG, Negishi M, Leary JA, Bertozzi CR. Discovery of estrogen sulfotransferase inhibitors from a purine library screen. *J Med Chem* 2001;44:2683-6.
14. Wu TY, Ding S, **Gray NS**, Schultz PG. Solid-phase synthesis of 2,3,5-trisubstituted indoles. *Org Lett* 2001;3:3827-30.
15. Harmse L, van Zyl R, **Gray N**, Schultz P, Leclerc S, Meijer L, Doerig C, Havlik I. Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of *Plasmodium falciparum*. *Biochem Pharmacol* 2001;62:341-8.
16. Chang YT, Wignall SM, Rosania GR, **Gray NS**, Hanson SR, Su AI, Merlie J Jr, Moon HS, Sangankar SB, Perez O, Heald R, Schultz PG. Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. *J Med Chem* 2001;44:4497-500.
17. Ding S, **Gray NS**, Ding Q, Schultz PG. Expanding the diversity of purine libraries. *Tetrahedron Lett* 2001;42:8751-5.
18. Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malim MH, **Gray NS**, Schaffer PA. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. *J Virol* 2002;76:7874-82.
19. Ding S, **Gray NS**, Wu X, Ding Q, Schultz PG. A combinatorial scaffold approach toward kinase-directed heterocycle libraries. *J Am Chem Soc* 2002;124:1594-6.
20. Ding S, **Gray NS**, Ding Q, Wu X, Schultz PG. Resin-capture and release strategy toward combinatorial libraries of 2,6,9-substituted purines. *J Comb Chem* 2002;4:183-6.
21. Chang YT, Choi G, Bae YS, Burdett M, Moon HS, Lee JW, **Gray NS**, Schultz PG, Meijer L, Chung SK, Choi KY, Suh PG, Ryu SH. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. *Chembiochem* 2002;3:897-901.
22. Wu X, Ding S, Ding Q, **Gray NS**, Schultz PG. A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells. *J Am Chem Soc* 2002;124:14520-1.
23. Knockaert M, Lenormand P, **Gray N**, Schultz P, Pouyssegur J, Meijer L. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. *Oncogene* 2002;21:6413-24.
24. Chao SH, Walker JR, Chanda SK, **Gray NS**, Caldwell JS. Identification of homeodomain proteins, PBX1 and PREP1, involved in the transcription of murine leukemia virus. *Mol Cell Biol* 2003;23:831-41.

25. Ding S, Wu TY, Brinker A, Peters EC, Hur W, **Gray NS**, Schultz PG. Synthetic small molecules that control stem cell fate. *Proc Natl Acad Sci U S A* 2003;100:7632-7.
26. Wu X, Ding S, Ding Q, **Gray NS**, Schultz PG. Small molecules that induce cardiomyogenesis in embryonic stem cells. *J Am Chem Soc* 2004;126:1590-1.
27. Wignall SM, **Gray NS**, Chang YT, Juarez L, Jacob R, Burlingame A, Schultz PG, Heald R. Identification of a novel protein regulating microtubule stability through a chemical approach. *Chem Biol* 2004;11:135-46.
28. Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, **Gray NS**. Synthesis and target identification of hymenialdisine analogs. *Chem Biol* 2004;11:247-59.
29. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, **Gray N**, Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. *J Biol Chem* 2004;279:13839-48.
30. Luesch H, Wu TY, Ren P, **Gray NS**, Schultz PG, Supek F. A genome-wide overexpression screen in yeast for small-molecule target identification. *Chem Biol* 2005;12:55-63.
31. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, Totzke F, Schachtele C, Lerman AS, Carnero A, Wan Y, **Gray N**, Meijer L. Roscovitine targets, protein kinases and pyridoxal kinase. *J Biol Chem* 2005;280:31208-19.
32. Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S, Reinhardt J, Ferandin Y, Galons H, Wan Y, **Gray N**, Meijer L, Jiang T, Liang DC. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. *J Biol Chem* 2005;280:31220-9.
33. Han S, Zhou V, Pan S, Liu Y, Hornsby M, McMullan D, Klock HE, Haugen J, Lesley SA, **Gray N**, Caldwell J, Gu XJ. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. *Bioorg Med Chem Lett* 2005;15:5467-73.
34. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, **Gray NS**. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. *Nat Chem Biol* 2006;2:95-102.
35. Zhang Q, Liu Y, Gao F, Ding Q, Cho C, Hur W, Jin Y, Uno T, Joazeiro CA, **Gray N**. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. *J Am Chem Soc* 2006;128:2182-3.
36. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, Jarnes L, Matzen JT, Garcia ME, Hood TL, Beigi R, Xia G, Harig RA, Asatryan H, Yan SF, Zhou Y, Gu XJ, Saadat A, Zhou V, King FJ, Shaw CM, Su AI, Downs R, **Gray NS**, Schultz PG, Warmuth M, Caldwell JS. An efficient rapid system for profiling the cellular activities of molecular libraries. *Proc Natl Acad Sci U S A* 2006;103:3153-8.

37. Choi HS, Wang Z, Richmond W, He X, Yang K, Jiang T, Sim T, Karanewsky D, Gu XJ, Zhou V, Liu Y, Ohmori O, Caldwell J, **Gray N**, He Y. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1. *Bioorg Med Chem Lett* 2006;16:2173-6.
38. Choi HS, Wang Z, Richmond W, He X, Yang K, Jiang T, Karanewsky D, Gu XJ, Zhou V, Liu Y, Che J, Lee CC, Caldwell J, Kanazawa T, Umemura I, Matsuura N, Ohmori O, Honda T, **Gray N**, He Y. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. *Bioorg Med Chem Lett* 2006;16:2689-92.
39. Okram B, Nagle A, Adrian FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, **Gray NS**. A general strategy for creating "inactive-conformation" abl inhibitors. *Chem Biol* 2006;13:779-86.
40. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, Hinterding K, Nuesslein-Hildesheim B, Tuntland T, Lefebvre S, Liu Y, Gao W, Chu A, Brinkmann V, Bruns C, Streiff M, Cannet C, Cooke N, **Gray N**. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. *Chem Biol*. 2006;13(11):1227-34.
41. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, **Gray NS**, Warmuth M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. *Proc Natl Acad Sci USA*. 2007;104(1):270-5.
42. Hong J, Lee J, Min KH, Walker JR, Peters EC, **Gray NS**, Cho CY, Schultz PG. Identification and characterization of small-molecule inducers of epidermal keratinocyte differentiation. *ACS Chem Biol*. 2007;2(3):171-5.
43. Jansma A, Zhang Q, Li B, Ding Q, Uno T, Bursulaya B, Liu Y, Furet P, **Gray NS**, Geierstanger BH: Verification of a Designed Intramolecular Hydrogen Bond in a Drug Scaffold by Nuclear Magnetic Resonance Spectroscopy. *J Med Chem*. 2007;50(24):5875-7.
44. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma X-J, Erlander MG, **Gray NS**, Haber DA, Settleman J: Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. *Proc Natl Acad Sci USA* 2007;104(50):19936-41.
45. Supekova L, Supek F, Lee J, Chen S, **Gray N**, Pezacki JP, Schlapbach A, Schultz PG. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. *J Biol Chem*. 2008;283(1):29-36.
46. Andersen CB, Wan Y, Chang JW, Riggs B, Lee C, Liu Y, Sessa F, Villa F, Kwiatkowski N, Suzuki M, Nallan L, Heald R, Musacchio A, **Gray NS**. Discovery of Selective Aminothiazole Aurora Kinase Inhibitors. *ACS Chem Biol*. 2008;3(3):180-92.

47. Kato N, Sakata T, Breton G, Le Roch KG, Nagle A, Andersen C, Bursulaya B, Henson K, Johnson J, Kumar KA, Marr F, Mason D, McNamara C, Plouffe D, Ramachandran V, Spooner M, Tuntland T, Zhou Y, Peters EC, Chatterjee A, Schultz PG, Ward GE, **Gray N**, Harper J, Winzeler EA. Gene expression signatures and small-molecule compounds link a protein kinase to *Plasmodium falciparum* motility. *Nat Chem Biol*. 2008;4(6):347-56.
48. McDermott U, Iafrate AJ, **Gray NS**, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. *Cancer Res*. 2008;68(9):3389-95.
49. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrián F, Matzen JT, Anderson P, Nam TG, **Gray NS**, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. *Proc Natl Acad Sci U S A*. 2008;105(26):9059-64.
50. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, **Gray NS**, Lee C, Meyerson M, Jänne PA. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res*. 2008;14(13):4275-83.
51. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, **Gray NS**. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. *Bioorg Med Chem Lett*. 2008;18(22):5916-9.
52. Zhang G, Ren P, **Gray NS**, Sim T, Liu Y, Wang X, Che J, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Chow D, Martin Seidel H, Karanewsky DS, He Y. Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I. *Bioorg Med Chem Lett*. 2008;18(20):5618-21.
53. Azam M, Seeliger MA, **Gray NS**, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. *Nat Struct Mol Biol*. 2008;15(10):1109-18.
54. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, **Gray NS**, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. *Nature*. 2008;455(7215):975-8.
55. Avni D, Goldsmith M, Ernst O, Mashiach R, Tuntland T, Meijler MM, **Gray NS**, Rosen H, Zor T. Modulation of TNF $\alpha$ , IL-10 and IL-12p40 levels by a ceramide-1-phosphate analog, PCERA-1, in vivo and ex vivo in primary macrophages. *Immunol Lett*. 2009;123(1)1-8.
56. Sáenz JB, Sun WJ, Chang JW, Li J, Bursulaya B, **Gray NS**, Haslam DB. Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. *Nat Chem Biol*. 2009;5(3):157-65.

57. Iacob RE, Pene-Dumitrescu T, Zhang J, **Gray NS**, Smithgall TE, Engen JR. Conformational disturbance in Abl kinase upon mutation and deregulation. *Proc Natl Acad Sci U S A*. 2009; 106(5):1386-91.
58. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, **Gray NS**. An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. *J Biol Chem*. 2009;284(12):8023-32.
59. Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, **Gray NS**, Jonkers J, Rosen JM, Brugge JS. Fibroblast Growth Factor Receptor 1-Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival. *Cancer Res*. 2009;69(6):2244-51.
60. Goldsmith M, Avni D, Levy-Rimler G, Mashiach R, Ernst O, Levi M, Webb B, Meijler MM, **Gray NS**, Rosen H, Zor T. A ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour necrosis factor-alpha and induces interleukin-10 production in activated macrophages. *Immunology*. 2009;127(1):103-15.
61. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, **Gray NS**, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* 2009;137(5):873-86.
62. Choi Y, Syeda F, Walker JR, Finerty PJ Jr, Cuerrier D, Wojciechowski A, Liu Q, Dhe-Paganon S, **Gray NS**. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. *Bioorg Med Chem Lett* 2009;19(15):4467-70.
63. Choi Y, Seeliger MA, Panjarian SB, Kim H, Deng X, Sim T, Couch B, Koleske AJ, Smithgall TE, **Gray NS**. N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor. *J Biol Chem*. 2009;284(42):29005-14.
64. Zhang G, Ren P, **Gray NS**, Sim T, Wang X, Liu Y, Che J, Dong W, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Wang Z, Seidel HM, Karanewsky DS, He Y. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. *Bioorg Med Chem Lett*. 2009;19(23):6691-5.
65. Wu T, Nagle A, Sakata T, Henson K, Borboa R, Chen Z, Kuhlen K, Plouffe D, Winzeler E, Adrian F, Tuntland T, Chang J, Simerson S, Howard S, Ek J, Isbell J, Deng X, **Gray NS**, Tully DC, Chatterjee AK. Cell-based optimization of novel benzamides as potential antimalarial leads. *Bioorg Med Chem Lett*. 2009;19(24):6970-4.
66. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, **Gray NS**, Sellers WR, Dummer R, Garraway LA. MEK1 mutations confer resistance to MEK and B-RAF inhibition. *Proc Natl Acad Sci U S A*. 2009;106(48):20411-6.
67. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, **Gray NS**, Jänne PA. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature*. 2009;462(7276):1070-4 (Gray and Jänne, co-corresponding authors)

68. Zhang J., Adrián, FJ, Jahnke W, Cowan-Jacob SW, Allen G, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun G, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N., Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, **Gray NS**. Targeting wild-type and T315I Bcr-Abl by combining allosteric with ATP-site inhibitors. *Nature*. 2010;463(7280):501-6.
69. McDermott U, Pusapati RV, Christensen JG, **Gray NS**, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. *Cancer Res*. 2010;70(4):1625-34.
70. Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fenrich G, Strauss A, Zhang J, **Gray NS**, Adrian F, Warmuth M, Pelle X, Grotzfeld R, Berst F, Marzinzik A, Cowan-Jacob SW, Furet P, Mestan J. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. *Biochim Biophys Acta*. 2010;1804(3):454-62.
71. Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, **Gray N**, Griffin JD. Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR Kit, and Src kinase. *Blood*. 2010;115(21):4206-16.
72. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M, Settleman J, **Gray NS**. A structure-guided approach to creating covalent FGFR inhibitors. *Chem Biol* 2010;17(3):285-95.
73. Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, **Gray NS**. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. *Nat Chem Biol*. 2010;6(5):359-68.
74. Hur W, Sun Z, Jiang T, Mason DE, Peters EC, Zhang DD, Luesch H, Schultz PG, **Gray NS**. A small-molecule inducer of the antioxidant response element. *Chem Biol*. 2010;17(5):537-47.
75. Deng X, Lim SM, Zhang J, **Gray NS**. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. *Bioorg Med Chem Lett*. 2010;20(14):4196-200.
76. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, **Gray NS**, Sim T. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. *J Med Chem*. 2010;53(15):5439-48.
77. Deng X, Nagle A, Wu T, Sakata T, Henson K, Chen Z, Kuhlen K, Plouffe D, Winzeler E, Adrian F, Tuntland T, Chang J, Simerson S, Howard S, Ek J, Isbell J, Tully DC, Chatterjee AK, **Gray NS**. Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. *Bioorg Med Chem Lett*. 2010;20(14):4027-31.

78. Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, **Gray NS**, Griffin JD. Discovery and characterization of novel mutant FLT3 kinase inhibitors. *Mol Cancer Ther.* 2010;9(9):2468-77.
79. Deng X, Okram B, Ding Q, Zhang J, Choi Y, Adrián FJ, Wojciechowski A, Zhang G, Che J, Bursulaya B, Cowan-Jacob SW, Rummel G, Sim T, **Gray NS**. Expanding the diversity of allosteric bcr-abl inhibitors. *J Med Chem.* 2010;53(19):6934-46.
80. Yang Q, Deng X, Lu B, Cameron M, Fearn C, Patricelli MP, Yates JR 3rd, **Gray NS**, Lee JD. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. *Cancer Cell.* 2010;18(3):258-67. Erratum in: *Cancer Cell.* 2010;18(4):396.
81. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, **Gray NS**. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. *J Med Chem.* 2010;53(19):7146-55.
82. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Adelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman C, Park SI, Kim HR, Padera R, Marto JA, **Gray NS**, Kung AL, Shapiro GI, Jänne PA, Wong KK. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. *Cancer Res.* 2010;70(23):9827-36.
83. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, **Gray NS**, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. *Cancer Res.* 2010;70(24):10038-43.
84. Zhou W, Ercan D, Jänne PA, **Gray NS**. Discovery of selective irreversible inhibitors for EGFR-T790M. *Bioorg Med Chem Lett.* 2011;21(2):638-43.
85. Jacob RE, Zhang J, **Gray NS**, Engen JR. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. *PLoS One.* 2011;6(1):e15929.
86. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, **Gray NS**. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. *J Med Chem.* 2011;54(5):1473-80.
87. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, **Gray NS**. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. *Nat Chem Biol.* 2011;7(4):203-5.
88. Deng X, Yang Q, Kwiatkowski N, Sim T, McDermott U, Settleman JE, Lee JD, **Gray NS**. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(1H)-one as a Potent and Selective Inhibitor of Big MAP Kinase *ACS Med Chem Lett.* 2011;2(3):195-200. Jan 12.



89. Deng X, Wang J, Zhang J, Sim T, Kim ND, Sasaki T, Luther W 2nd, George RE, Jänne PA, **Gray NS**. Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. *ACS Med Chem Lett*. 2011;2(5):379-384.
90. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Choi HG, Waller DL, Sim T, Sabatini DM, **Gray NS**. Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsomal stability. *Bioorg Med Chem Lett*. 2011;21(13):4036-40.
91. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, **Gray NS**, Yaffe MB, Marto JA, Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science*. 2011;332(6035):1317-22.
92. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, **Gray NS**, Meyerson M. Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. *PLoS One*. 2011;6(6):e20351.
93. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, Jagannathan S, Aban A, Okerberg E, Herring C, Nordin B, Weissig H, Yang Q, Lee JD, **Gray NS**, Kozarich JW. In situ kinase profiling reveals functionally relevant properties of native kinases. *Chem Biol*. 2011;18(6):699-710.
94. McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, **Gray NS**, Richardson PG, Anderson KC, Kung AL, Mitsiades CS. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. *PLoS One*. 2011;6(7):e20226.
95. Miduturu CV, Deng X, Kwiatkowski N, Yang W, Brault L, Filippakopoulos P, Chung E, Yang Q, Schwaller J, Knapp S, King RW, Lee JD, Herrgard S, Zarrinkar P, **Gray NS**. High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors. *Chem Biol*. 2011;18(7):868-79.
96. Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, **Gray NS**. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. *ACS Chem Biol*. 2012 Jan 20;7(1):185-96.
97. Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, **Gray NS**. Development of ATP-competitive mTOR inhibitors. *Methods Mol Biol*. 2012;821:447-60.
98. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, **Gray NS**. Kinome-wide selectivity profiling of ATP-competitive mTOR (mammalian target of rapamycin) inhibitors and characterization of their binding kinetics. *J Biol Chem*. 2012.
99. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, Lograsso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR,

- Gray NS.** Discovery of Potent and Selective Covalent Inhibitors of JNK. *Chem Biol.* 2012;19(1):140-54.
100. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS. Characterization of TAE684 as a potent LRRK2 kinase inhibitor. *Bioorg Med Chem Lett.* 2012; 22(5):1864-9. Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
101. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, **Gray NS**, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature.* 2012 Mar 28;483(7391):570-5.
102. Liu Q, Ren T, Fresques T, Oppliger W, Niles BJ, Hur W, Sabatini DM, Hall MN, Powers T, **Gray NS.** Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in *Saccharomyces cerevisiae*. *ACS Chem Biol.* 2012, 7 (6), 982–987.
103. Hellwig S, Miduturu CV, Kanda S, Zhang J, Filippakopoulos P, Salah E, Deng X, Choi HG, Zhou W, Hur W, Knapp S, **Gray NS**, Smithgall TE. Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase. *Chem Biol.* 2012 Apr 20;19(4):529-40.
104. Thoreen CC, Chantranupong L, Keys HR, Wang T, **Gray NS**, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature.* 2012 May 2;485(7396):109-13.
105. Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, **Gray NS.** Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors. *Leukemia.* 2012 Apr 3. doi: 10.1038/leu.2012.96.
106. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, **Gray NS**, Zhao J. Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110 $\beta$  as a Potential Anticancer Agent. *Cancer Discov.* 2012 May;2(5):425-33.
107. Zhang Z, Kwiatkowski N, Zeng H, Lim SM, **Gray NS**, Zhang W, Yang PL. Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy. *Mol Biosyst.* 2012 Oct;8(10):2523-6.
108. Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, **Gray NS**, Cohen P, Pedrioli P, Clark K, Alessi DR. The IkappaB Kinase Family Phosphorylates the Parkinson's Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling. *PLoS One.* 2012;7(6):e39132.

109. Deng X, Zhou W, Weisberg E, Wang J, Zhang J, Sasaki T, Nelson E, Griffin JD, Jänne PA, **Gray NS**. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFR $\alpha$  and kit. *Bioorg Med Chem Lett*. 2012 Jul 15;22(14):4579-84.
110. Choi HG, Zhang J, Weisberg E, Griffin JD, Sim T, **Gray NS**. Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. *Bioorg Med Chem Lett*. 2012 Aug 15;22(16):5297-302.
111. Lau KS, Zhang T, Kendall KR, Lauffenburger D, **Gray NS**, Haigis KM. BAY61-3606 Affects the Viability of Colon Cancer Cells in a Genotype-Directed Manner. *PLoS One*. 2012;7(7):e41343.
112. Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, **Gray NS**, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. *Proc Natl Acad Sci U S A*. 2012 Jul 31;109(31):12722-7.
113. Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, **Gray NS**, Hornicek FJ. Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation. 2012 Sep 1;18(17):4580-8. Epub 2012 Jul 12.
114. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, **Gray NS**, Pearson AD, Eccles SA, Chesler L, George RE. The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. *Cancer Cell*. 2012 Jul 10;22(1):117-30.
115. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, **Gray NS**, Wong KK, Jänne PA. Reactivation of ERK Signaling causes resistance to EGFR kinase inhibitors. *Cancer Discov*. 2012 Oct;2(10):934-47.
116. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, **Gray NS**. GSK2578215A; A potent and highly selective 2-arylmethoxy-5-substituent-N-arylbenzamide LRRK2 kinase inhibitor. *Bioorg Med Chem Lett*. 2012 Sep 1;22(17):5625-9.
117. Clark K, Mackenzie KF, Petkevicius K, Kristariyanto Y, Zhang J, Choi HG, Peggie M, Plater L, Pedrioli PG, McIver E, **Gray NS**, Arthur JS, Cohen P. Phosphorylation of CRT3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. *Proc Natl Acad Sci U S A*. 2012 Oct 16;109(42):16986-91.
118. Choi HG, Zhang J, Deng X, Hatcher JM, Patricelli MP, Zhao Z, Alessi DR, **Gray NS**. Brain Penetrant LRRK2 Inhibitor. *ACS Med Chem Lett*. 2012 Aug 9;3(8):658-662.
119. Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, **Gray NS**, Jänne PA. Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. *Cancer Res*. 2013. Jan 15;73(2):834-43.

120. Guo Y, Chekaluk Y, Zhang J, Du J, **Gray NS**, Wu CL, Kwiatkowski DJ. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. *J Pathol.* 2013 May; 230(1):17-27.
121. Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, **Gray NS**. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR. *Cancer Res.* 2013 Apr 15;73(8):2574-86.
122. Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, **Gray NS**. Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. *PLoS One.* 2013;8(2):e56473.
123. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher M, Neuberg D, Levine RL, Moriggl R, Muller M, **Gray NS**, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia. *Cancer Discov.* 2013 Mar 7.
124. Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, **Gray NS**. Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. *ACS Chem Biol.* 2013 Jul 19;8(7):1423-8.
125. Elkins JM, Wang J, Deng X, Pattison MJ, Arthur JS, Erazo T, Gomez N, Lizcano JM, **Gray NS**, Knapp S. X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. *J Med Chem.* 2013 Jun 13;56(11):4413-21
126. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman AC, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, **Gray NS**, Root DE, Cantley LC, Wong KK. Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer. *Cancer Discov.* 2013 May 28.
127. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Joseph SB, Kim Y, Tuntland T, Cui X, **Gray NS**, Steensma R, Wan Y, Jiang J, Li J, Chopiuck G, Gordon WP, Li AG, Richmond W, Chang J, Groessl T, He YQ, Liu B, Phimister A, Aycinena A, Bursulaya B, Lee C, Karanewsky DS, Seidel HM, Harris JL, Michellys PY. Synthesis, Structure-Activity Relationships and In Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor LDK378 Currently In Phase 1 and 2 Clinical Trials. *J Med Chem.* 2013 Jun 6.
128. Liao RG, Jung J, Tchaicha JH, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, **Gray NS**, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. *Cancer Res.* 2013 Jun 20.
129. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, **Gray NS**, Lindquist S. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. *Nat Biotechnol.* 2013 Jul;31(7):630-7.
130. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, **Gray N**, Tai YT, Anderson KC, Hunter ZR, Treon SP. A mutation in MYD88 (L265P) supports the survival of

- lymphoplasmacytic cells by activation of Bruton's tyrosine kinase in Waldenstrom's macroglobulinemia. *Blood*. 2013 Aug 15;122(7):1222-32.
131. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, **Gray NS**, Turk BE, Yaffe MB, Sabatini DM. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. *Science*. 2013 Jul 26;341(6144):1236566.
132. Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, **Gray NS**. Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor. *ACS Chem Biol*. 2013 Oct 18;8(10):2145-50.
133. Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, Geerts D, De Witt Hamer PC, Hagemann C, Vandertop WP, Van Tellingen O, Noske DP, **Gray NS**, Würdinger T. Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. *J Natl Cancer Inst*. 2013 Sep 4;105(17):1322-31.
134. Mistry H, Hsieh G, Buhrlage SS, Huang M, Park E, Cuny GD, Galinsky I, Stone R, **Gray NS**, D'Andrea AD, Parmar K. Small molecule inhibitors of USP1 target ID1 degradation in leukemic cells. *Mol Cancer Ther*. 2013 Dec;12(12):2651-62.
135. Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, Choi HG, Wang J, Dzamko N, Lee JD, Sim T, Kim N, Alessi DR, Lizcano JM, Knapp S, **Gray NS**. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. *Eur J Med Chem*. 2013 Oct 29;70C:758-767.
136. Banerjee S, Buhrlage SJ, Huang HT, Deng X, Zhou W, Wang J, Traynor R, Prescott AR, Alessi DR, **Gray NS**. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1 tumour suppressor activated NUAK kinases. *Biochem J*. 2014 Jan 1;457(1):215-25.
137. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, **Gray NS**. Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor. *Angew Chem Int Ed Engl*. 2014 Jan 3;53(1):199-204.
138. Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, **Gray NS**, Bass AJ, Wong KK, Meyerson M, Hammerman PS. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. *Mol Cancer Ther*. 2014 Jan 23.
139. Ficarro SB, Biagi JM, Wang J, Scotcher J, Koleva RI, Card JD, Adelmant G, He H, Askenazi M, Marshall AG, Young NL, **Gray NS**, Marto JA. Protected Amine Labels: A Versatile Molecular Scaffold for Multiplexed Nominal Mass and Sub-Da Isotopologue Quantitative Proteomic Reagents. *J Am Soc Mass Spectrom*. 2014 Feb 5.
140. Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, **Gray NS**. Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. *ACS Chem Biol*. 2014 May 16;9(5):1086-91.
141. Decker S, Finter J, Forde A, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray NS, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu C, Eibel H, Veelken H, Dierks C. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4 mediated microenvironmental interactions (PIM1). *Mol Cancer Ther*. 2014 May;13(5):1231-45.
142. Codeluppi S, Fernandez-Zafra T, Sandor K, Kjell J, Liu Q, Abrams M, Olson L, Gray NS, Svensson CI, Uhlén P. Interleukin-6 Secretion by Astrocytes Is Dynamically Regulated by PI3K-mTOR-Calcium Signaling. *PLoS One*. 2014 Mar 25;9(3):e92649.
143. Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. *J Clin Invest*. 2014 May;124(5):2037-49.

144. Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN. Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors. *J Mol Biol.* 2014 Apr 23.
145. Vetter ML, Zhang Z, Liu S, Wang J, Cho H, Zhang J, Zhang W, Gray NS, Yang PL. Fluorescent Visualization of Src by Using Dasatinib-BODIPY. *Chembiochem.* 2014 May 14.
146. Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. *Elife.* 2014 May 20;3:e01763.
147. Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. *Proc Natl Acad Sci U S A.* 2014 Jun 17;111(24):8895-900.
148. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature.* 2014 Jul 31; 511: 616–620.
149. Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS. Discovery of Type II Inhibitors of TGF $\beta$ -Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2). *J Med Chem.* 2014 Jul 30.
150. Patel K, Foretz M, Marion A, Campbell DG, Gourlay R, Boudaba N, Tournier E, Titchenell P, Peggie M, Deak M, Wan M, Kaestner KH, Göransson O, Viollet B, Gray NS, Birnbaum MJ, Sutherland C, Sakamoto K. The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. *Nat Commun.* 2014.
151. Theunissen TW, Powell BE, Wang H, Mitalipova M, Faddah DA, Reddy J, Fan ZP, Maetzel D, Ganz K, Shi L, Lungjangwa T, Imsoonthornruksa S, Stelzer Y, Rangarajan S, D'Alessio A, Zhang J, Gao Q, Dawlaty MM, Young RA, Gray NS, Jaenisch R. Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency. *Cell Stem Cell.* 2014 Jul 24.
152. Derbyshire ER, Zuzarte-Luís V, Magalhães AD, Kato N, Sanschagrín PC, Wang J, Zhou W, Miduturu CV, Mazitschek R, Sliz P, Mota MM, Gray NS, Clardy J. Chemical Interrogation of the Malaria Kinome. *Chembiochem.* 2014 Aug 8: 15, 1920-30.
153. Sundberg TB, Choi HG, Song JH, Russell CN, Hussain MM, Graham DB, Khor B, Gagnon J, O'Connell DJ, Narayan K, Danc(ík V, Perez JR, Reinecker HC, Gray NS, Schreiber SL, Xavier RJ, Shamji AF. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. *Proc Natl Acad Sci U S A.* 2014 Aug 26: 111(34), 12468-12473.
154. Ritorto MS, Ewan R, Perez-Oliva AB, Knebel A, Buhrlage SJ, Wightman M, Kelly SM, Wood NT, Virdee S, Gray NS, Morrice NA, Alessi DR, Trost M. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. *Nat Commun.* 2014 Aug 27.
155. Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray NS, Esparís-Ogando A, David E, Pandiella A, Dello Sbarba P, Parola M, Marra F. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. *Gut.* 2014 Sep 2.
156. Weisberg EL, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades CS, Wong KK, Liu Q, Gray NS, Griffin JD. Up-regulation of IGF-1R by mutant RAS in

- leukemia and potentiation of RAS signaling inhibitors by small molecule inhibition of IGF-1R. *Clin Cancer Res.* 2014 Sep 3.
157. Chaikuad A, M C Tacconi E, Zimmer J, Liang Y, Gray NS, Tarsounas M, Knapp S. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. *Nat Chem Biol.* 2014 Sep 7.
158. Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. *Mol Oncol.* 2014 Aug 29.
159. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. *Oncotarget.* 2014 Aug 19.
160. Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. *BMC Cancer.* 2014 Sep 19;14:681.
161. Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH. Response and acquired resistance to everolimus in anaplastic thyroid cancer. *N Engl J Med.* 2014 Oct 9;371(15):1426-33.
162. Huang Z, Tan L, Wang H, Liu Y, Blais S, Deng J, Neubert TA, Gray NS, Li X, Mohammadi M. DFG-out Mode of Inhibition by an Irreversible type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors. *ACS Chem Biol.* 2014 Oct 15.
163. Lopez-Pelaez M, Lamont DJ, Peggie M, Shpiro N, Gray NS, Cohen P. Protein kinase IKK $\beta$ -catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells. *Proc Natl Acad Sci U S A.* 2014 Oct 17.
164. Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Pharmacological targeting of the pseudokinase Her3. *Nat Chem Biol.* 2014 Oct 19.
165. Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. *Proc Natl Acad Sci U S A.* 2014 Nov 11;111(45):E4869-77.
166. Umopathy G, El Wakil A, Witek B, Chesler L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth K, Schönherr C, Palmer RH, Hallberg B. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. *Sci Signal.* 2014 Oct 28;7(349):ra102.
167. Moroco JA, Baumgartner MP, Rust HL, Choi HG, Hur W, Gray NS, Camacho CJ, Smithgall TE. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region. *Chem Biol Drug Des.* 2014 Nov 6.
168. Gray NS, Fabbro D. Discovery of allosteric bcr-abl inhibitors from phenotypic screen to clinical candidate. *Methods Enzymol.* 2014;548:173-88.
169. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, Gray NS, Young RA, George RE. CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer. *Cell.* 2014 Nov 20;159(5):1126-39.
170. Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB,

- Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK. Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. *Cancer Cell*. 2014 Dec 8;26(6):909-22.
171. Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. *Cancer Discov*. 2015 Mar;5(3):274-87.
172. Fallahi-Sichani M, Moerke NJ, Niepel M, Zhang T, Gray NS, Sorger PK. Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. *Mol Syst Biol*. 2015 Mar 26;11(3):797.
173. Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacological approach. *Blood*. 2015 Apr 1
174. Malik N, Vollmer S, Nanda SK, Lopez-Pelaez M, Prescott A, Gray N, Cohen P. Suppression of Interferon  $\beta$  gene transcription by inhibitors of Bromodomain and Extra-Terminal (BET) family members. *Biochem J*. 2015 Apr 20
175. Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Janne PA. EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors. *Clin Cancer Res*. 2015 May 6.
176. Hatcher JM, Zhang J, Choi HG, Ito G, Alessi DR, Gray NS. Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. *ACS Med Chem Lett*. 2015 Apr 7;6(5):584-9.
177. Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Janne PA. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR mutant Lung Cancer. *Cancer Discov*. 2015 Jun 2. pii: CD-15-0063.
178. Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. *PLoS One*. 2015 Jun 5;10(6):e0128364.
179. Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Development of small molecules targeting the pseudokinase Her3. *Bioorg Med Chem Lett*. 2015 Aug 15;25(16):3382-9.
180. Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella KM, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, Look AT, Arthur S, Eck MJ, Gray NS. Development of Selective Covalent JAK3 Inhibitors. *J Med Chem*. 2015 Aug 27;58(16):6589-606.
181. Wilhelmsen K, Xu F, Farrar K, Tran A, Khakpour S, Sundar S, Prakash A, Wang J, Gray NS, Hellman J. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. *Sci Signal*. 2015 Aug 25;8(391):ra86.
182. Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, Zhao P, Wang J, Wang C, Weisberg EL, Gray NS, Yun CH, Liu J, Chen L, Liu Q. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. *Oncotarget*. 2015 Oct 13;6(31):31313-22.
183. Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Non-small Cell Lung. *ACS Chem Biol*. 2015 Dec 18;10(12):2687-96.
184. Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. *Cell*. 2015 Sep 24;163(1):174-86.



185. Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, Pepe-Mooney B, Zhang T, Geeven G, Gray NS, de Laat W, Calogero RA, Camargo FD. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. *Mol Cell*. 2015 Oct 15;60(2):328-37.
186. Hatcher JM, Bahcall M, Choi HG, Gao Y, Sim T, George R, Janne PA, Gray NS. Discovery of inhibitors that overcome the G1202R ALK resistance mutation. *J Med Chem*. 2015 Dec 10;58(23):9296-308.
187. Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, Cote G, Harmon D, Mankin H, Gray NS, Hornicek FJ, Duan Z. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (Pgp) function. *Br J Pharmacol*. 2016 Feb;173(3):613-26.
188. Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, Gray NS, Druker BJ, Tyner JW. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. *Cancer Res*. 2016 Jan 1;76(1):127-38.
189. Neel VA, Todorova K, Wang J, Kwon E, Kang M, Liu Q, Gray N, Lee SW, Mandinova A. Sustained Akt activity is required to maintain cell viability in seborrheic keratosis, a benign epithelial tumor. *J Invest Dermatol*. 2015 Dec 28.
190. Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. *Cancer Res*. 2016 Jan 15;76(2):305-18.
191. Nishikawa JL, Boeszoermyeni A, Vale-Silva LA, Torelli R, Posteraro B, Sohn YJ, Ji F, Gelev V, Sanglard D, Sanguinetti M, Sadreyev RI, Mukherjee G, Bhyravabhotla J, Buhrlage SJ, Gray NS, Wagner G, Näär AM, Arthanari H. Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction. *Nature*. 2016 Feb 25;530(7591):485-9.
192. Ho CM, Donovan-Banfield IZ, Tan L, Zhang T, Gray NS, Strang BL. Inhibition of IKK $\alpha$  by BAY61-3606 Reveals IKK $\alpha$ -Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells. *PLoS One*. 2016 Mar 1;11(3):e0150339.
193. Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, Patterson CJ, Castillo JJ, Buhrlage S, Gray N, Treon SP, Yang G. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. *Br J Haematol*. 2016 Apr 13. doi: 10.1111/bjh.14103.
194. Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen YF, Wang L, Gray NS, Liu J, Zhang X, Liu Q. Discovery of a Highly Selective STK16 Kinase Inhibitor. *ACS Chem Biol*. 2016 Jun 17;11(6):1537-43.
195. Clark MJ, Miduturu C, Schmidt AG, Zhu X, Pitts JD, Wang J, Potisopon S, Zhang J, Wojciechowski A, Hann Chu JJ, Gray NS, Yang PL. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. *Cell Chem Biol*. 2016 Apr 21;23(4):443-52.
196. Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu-Remaileh M, Shaul YD, Liu CM, Zhou M, Koh MJ, Chung H, Davidson SM, Luengo A, Wang AQ, Xu X, Yasgar A, Liu L, Rai G, Westover KD, Vander Heiden MG, Shen M, Gray NS, Boxer MB, Sabatini DM. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. *Nat Chem Biol*. 2016 Jun;12(6):452-8.
197. Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD. Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. *Radiat Res*. 2016 May;185(5):527-38.
198. Yang G, Buhrlage S, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP. HCK is a

- survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. *Blood*. 2016 Jun 23;127(25):3237-52.
199. Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, Verdun R, Gray NS, Lossos IS. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. *Blood*. 2016 Jul 14;128(2):239-48.
200. Hatcher JM, Weisberg E, Sim T, Stone RM, Liu S, Griffin JD, Gray NS. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. *ACS Med Chem Lett*. 2016 Mar 8;7(5):476-81.
201. Sundberg TB, Liang Y, Wu H, Choi HG, Kim ND, Sim T, Johannessen L, Petrone A, Khor B, Graham DB, Latorre IJ, Phillips AJ, Schreiber SL, Perez J, Shamji AF, Gray NS, Xavier RJ. Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function In Vivo. *ACS Chem Biol*. 2016 11(8):2105-2111.
202. Lee S, Shang Y, Redmond SA, Urisman A, Tang AA, Li KH, Burlingame AL, Pak RA, Jovicic A, Gitler AD, Wang J, Gray NS, Seeley WW, Siddique T, Bigio EH, Lee VM, Trojanowski JQ, Chan JR, Huang EJ. Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. *Neuron*. 2016 Jul 6;91(1):41-55.
203. Chong CR, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Janne PA. Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer. *Clin Cancer Res*. 2017 Jan 1;23(1):204-213.
204. Brown W, Tan L, Smith A, Gray NS, Wendt M. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. *Mol Cancer Ther*. 2016 Sep;15(9):2096-106.
205. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LF, Saez-Rodriguez J, McDermott U, Garnett MJ. A Landscape of Pharmacogenomic Interactions in Cancer. *Cell*. 2016 Jul 28;166(3):740-54.
206. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC Jr, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. *Cancer Cell*. 2016 Aug 8;30(2):273-89.
207. Williams CA, Fernandez-Alonso R, Wang J, Toth R, Gray NS, Findlay GM. Erk5 Is a Key Regulator of Naive-Primed Transition and Embryonic Stem Cell Identity. *Cell Rep*. 2016 Aug 16;16(7):1820-8.
208. Wang Y, Begley M, Li Q, Huang HT, Lako A, Eck MJ, Gray NS, Mitchison TJ, Cantley LC, Zhao JJ. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. *Proc Natl Acad Sci U S A*. 2016 Aug 30;113(35):9810-5.
209. Fan F, He Z, Kong LL, Chen Q, Yuan Q, Zhang S, Ye J, Liu H, Sun X, Geng J, Yuan L, Hong L, Xiao C, Zhang W, Sun X, Li Y, Wang P, Huang L, Wu X, Ji Z, Wu Q, Xia NS, Gray NS, Chen L, Yun CH, Deng X, Zhou D. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. *Sci Transl Med*. 2016 Aug 17;8(352):352ra108.
210. Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifengberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA,

- Geyer M, Bullock AN, Young RA, Gray NS. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. *Nat Chem Biol.* 2016 Oct;12(10):876-84.
211. Wang A, Yan XE, Wu H, Wang W, Hu C, Chen C, Zhao Z, Zhao P, Li X, Wang L, Wang B, Ye Z, Wang J, Wang C, Zhang W, Gray NS, Weisberg EL, Chen L, Liu J, Yun CH, Liu Q. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. *Oncotarget.* 2016 Oct 25;7(43):69760-69769.
212. Wein MN, Liang Y, Goransson O, Sundberg TB, Wang J, Williams EA, O'Meara MJ, Govea N, Beqo B, Nishimori S, Nagano K, Brooks DJ, Martins JS, Corbin B, Anselmo A, Sadreyev R, Wu JY, Sakamoto K, Foretz M, Xavier RJ, Baron R, Bouxsein ML, Gardella TJ, Divieti-Pajevic P, Gray NS, Kronenberg HM. SIKs control osteocyte responses to parathyroid hormone. *Nat Commun.* 2016 Oct 19;7:13176. doi: 10.1038/ncomms13176.
213. Ferguson FM, Ni J, Zhang T, Tesar B, Sim T, Kim ND, Deng X, Brown JR, Zhao JJ, Gray NS. Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K- $\delta/\gamma$  Inhibitors. *ACS Med Chem Lett.* 2016 Aug 2;7(10):908-912.
214. Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun C-H, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. *Leukemia* (2016) 30, 173–181
215. Hur W, Rosen H, Gray NS. A benzo[b]thiophene-based selective type 4 S1P receptor agonist. *Bioorg Med Chem Lett.* 2017 Jan 1;27(1):1-5.
216. Beelontally R, Wilkie GS, Lau B, Goodmaker CJ, Ho CM, Swanson CM, Deng X, Wang J, Gray NS, Davison AJ, Strang BL. Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins. *Antiviral Res.* 2017 Feb;138:61-67.
217. Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS. Structure-guided development of covalent TAK1 inhibitors. *Bioorg Med Chem.* 2017 Feb 1;25(3):838-846.
218. de Wispelaere M, Carocci M, Liang Y, Liu Q, Sun E, Vetter ML, Wang J, Gray NS, Yang PL. Discovery of host-targeted covalent inhibitors of dengue virus. *Antiviral Res.* 2017 Mar;139:171-179.
219. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. *Bioorg Med Chem.* 2017 Feb 15;25(4):1320-1328.
220. Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA, Stiles CD. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. *Neuro Oncol.* 2017 Jan 12. pii: now261. doi: 10.1093/neuonc/now261.
221. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS. Covalent Guanosine Mimetic Inhibitors of G12C KRAS. *ACS Med Chem Lett.* 2016 Nov 30;8(1):61-66. doi: 10.1021/acsmedchemlett.6b00373
222. Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudio M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. *Nat Commun.* 2017 Jan 30;8:14290. doi: 10.1038/ncomms14290.

223. Ficarro SB, Browne CM, Card JD, Alexander WM, Zhang T, Park E, McNally R, Dhe-Paganon S, Seo HS, Lamberto I, Eck MJ, Buhrlage SJ, Gray NS, Marto JA. Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. *Anal Chem*. 2016 Dec 20;88(24):12248-12254.
224. Majkowska I, Shitomi Y, Ito N, Gray NS, Itoh Y. Discoidin Domain Receptor 2 Mediates Collagen-Induced Activation of Membrane-Type 1 Matrix Metalloproteinase in Human Fibroblasts. *J Biol Chem*. 2017 Mar 7.
225. Liang Y, de Wispelaere M, Carocci M, Liu Q, Wang J, Yang PL, Gray NS. Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. *ACS Med Chem Lett*. 2017 Feb 3;8(3):344-349.
226. Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J, Yu K, Hu C, Wang W, Liu X, Deng Y, Wang L, Wang B, Li X, Gray NS, Liu J, Wei W, Liu Q. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. *Sci Rep*. 2017 Mar 28;7(1):466.
227. Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. *Sci Transl Med*. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.
228. Vollmer S, Strickson S, Zhang T, Gray N, Lee K, Rao V, Cohen P. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-Like receptor agonists. *Biochem J*. 2017 May 16. pii: BCJ20170097. doi: 10.1042/BCJ20170097.
229. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS. Discovery of a potent dual ALK and EGFR T790M inhibitor. *Eur J Med Chem*. 2017 Aug 18; 136: 497-510.
230. Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, Letai A, Root DE, Langer RS, Gray NS, Hahn WC. Synergistic interactions with PI3K inhibition that induce apoptosis. *Elife*. 2017 May 31;6. pii: e24523.
231. Williams CAC, Gray NS, Findlay GM. A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening. *J Vis Exp*. 2017 May 12;(123). doi: 10.3791/55515.
232. Mujahid N, Liang Y, Murakami R, Choi HG, Dobry AS, Wang J, Suita Y, Weng QY, Allouche J, Kemeny LV, Hermann AL, Roider EM, Gray NS, Fisher DE. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. *Cell Rep*. 2017 Jun 13;19(11):2177-2184. doi: 10.1016/j.celrep.2017.05.042.
233. Wang B, Deng Y, Chen Y, Yu K, Wang A, Liang Q, Wang W, Chen C, Wu H, Hu C, Miao W, Hur W, Wang W, Hu Z, Weisberg EL, Wang J, Ren T, Wang Y, Gray NS, Liu Q, Liu J. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. *Eur J Med Chem*. 2017 Jun 9;137:545-557. doi: 10.1016/j.ejmech.2017.06.016.
234. Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. *Mol Cell*. 2017 Jun 23. pii: S1097-2765(17)30406-9.

235. Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. *PLoS One*. 2017 Jul 20;12(7):e0181178.
236. Wong KK, Liu Y, Li Y, Wang X, Liu F, Gao P, Quinn MM, Li F, Merlino AA, Benes CH, Liu Q, Gray NS. Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma. *Cancer Res*. 2017 Jul 28. pii: canres.0567.2017.
237. Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Etmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, Luecking U, Michaelides M, Müller S, Muratov E, Denny RA, Saikatendu KS, Treiber DK, Zuercher WJ, Willson TM. Progress towards a public chemogenomic set for protein kinases and a call for contributions. *PLoS One*. 2017 Aug 2;12(8):e0181585.
238. Lu J, Harrison RA, Li L, Zeng M, Gondi S, Scott D, Gray NS, Engen JR, Westover KD. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. *Structure*. 2017 Sep 5;25(9):1442-1448.e3.
239. Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Jänne PA, Scott DA, Westover KD, Gray NS. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. *Cell Chem Biol*. 2017 Aug 17;24(8):1005-1016.e3.
240. Johannessen L, Sundberg TB, O'Connell DJ, Kolde R, Berstler J, Billings KJ, Khor B, Seashore-Ludlow B, Fassl A, Russell CN, Latorre IJ, Jiang B, Graham DB, Perez JR, Sicinski P, Phillips AJ, Schreiber SL, Gray NS, Shamji AF, Xavier RJ. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. *Nat Chem Biol*. 2017 Aug 14. doi: 10.1038/nchembio.2458.
241. Ferguson FM, Doctor ZM, Chaikuad A, Sim T, Kim ND, Knapp S, Gray NS. Characterization of a highly selective inhibitor of the Aurora kinases. *Bioorg Med Chem Lett*. 2017 Sep 15;27(18):4405-4408.
242. Gilbert AS, Seoane PI, Sephton-Clark P, Bojarczuk A, Hotham R, Giurisato E, Sarhan AR, Hillen A, Velde GV, Gray NS, Alessi DR, Cunningham DL, Tournier C, Johnston SA, May RC. Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5. *Sci Adv*. 2017 Aug 16;3(8):e1700898.
243. Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, Eck MJ, Dhe-Paganon S, Zhao JJ, Gray NS. MELK is not necessary for the proliferation of basal-like breast cancer cells. *Elife*. 2017 Sep 19;6. pii: e26693. doi: 10.7554/eLife.26693.
244. Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ. Inhibition of USP10 induces degradation of oncogenic FLT3. *Nat Chem Biol*. 2017 Dec;13(12):1207-1215. doi: 10.1038/nchembio.2486.
245. Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, Ishida T, Sanda T. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. *Blood*. 2017 Nov 23;130(21):2326-2338. doi: 10.1182/blood-2017-06-792184.
246. Kalan S, Amat R, Schachter MM, Kwiatkowski N, Abraham BJ, Liang Y, Zhang T, Olson CM, Larochelle S, Young RA, Gray NS, Fisher RP. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. *Cell Rep*. 2017 Oct 10;21(2):467-481. doi: 10.1016/j.celrep.2017.09.056.
247. Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, Leggett AL, Li T, Wang

- Y, Zhang T, Kim TJ, Hong SH, Poudel-Neupane N, Silkes M, Mudianto T, Tan L, Shimamura T, Meyerson M, Bass AJ, Watanabe H, Gray NS, Young RA, Wong KK, Hammerman PS. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. *Cancer Discov.* 2017 Oct 20. pii: CD-17-0461. doi: 10.1158/2159-8290.CD-17-0461.
248. Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK. CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation. *Cancer Discov.* 2018 Feb;8(2):216-233.
249. Huang HT, Dobrovolsky D, Paulk J, Yang G, Weisberg EL, Doctor ZM, Buckley DL, Cho JH, Ko E, Jang J, Shi K, Choi HG, Griffin JD, Li Y, Treon SP, Fischer ES, Bradner JE, Tan L, Gray NS. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. *Cell Chem Biol.* 2017 Nov 7. pii: S2451-9456(17)30386-0. doi: 10.1016/j.chembiol.2017.10.005
250. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao WN, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell.* 2017 Nov 30;171(6):1437-1452.e17. doi: 10.1016/j.cell.2017.10.049.
251. Wang L, Qiao Q, Ferrao R, Shen C, Hatcher JM, Buhrlage SJ, Gray NS, Wu H. Crystal structure of human IRAK1. *Proc Natl Acad Sci U S A.* 2017 Dec 19;114(51):13507-13512.
252. Weintraub AS, Li CH, Zamudio AV, Sigova AA, Hannett NM, Day DS, Abraham BJ, Cohen MA, Nabet B, Buckley DL, Guo YE, Hnisz D, Jaenisch R, Bradner JE, Gray NS, Young RA. YY1 Is a Structural Regulator of Enhancer-Promoter Loops. *Cell.* 2017 Dec 14;171(7):1573-1588.e28.
253. Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, Zhang T, Kwiatkowski N, Boukhali M, Green JL, Haas W, Nomanbhoy T, Fischer ES, Young RA, Bradner JE, Winter GE, Gray NS. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. *Nat Chem Biol.* 2017 Dec 18. doi: 10.1038/nchembio.2538.
254. Terai H, Kitajima S, Potter DS, Matsui Y, Gutierrez Quiceno L, Chen T, Kim TJ, Rusan M, Thai TC, Piccioni F, Donovan KA, Kwiatkowski N, Hinohara K, Wei G, Gray NS, Fischer ES, Wong KK, Shimamura T, Letai A, Hammerman PS, Barbie DA. ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors. *Cancer Res.* 2017 Dec 19.
255. Gao Y, Zhang T, Terai H, Ficarro SB, Kwiatkowski N, Hao MF, Sharma B, Christensen CL, Chipumuro E, Wong KK, Marto JA, Hammerman PS, Gray NS, George RE. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. *Cell Chem Biol.* 2017 Dec 15. pii: S2451-9456(17)30424-5.
256. Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D, Benes CH, Young RA, Gray NS, Stegmaier K. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. *Cancer Cell.* 2018 Feb 12;33(2):202-216.e6. doi: 10.1016/j.ccell.2017.12.009. Epub 2018 Jan 18.
257. Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A,

- Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC Jr., Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. *Nat Commun.* 2018 Feb 2;9(1):476. doi: 10.1038/s41467-017-02811-7.
258. Eliades P, Abraham BJ, Ji Z, Miller DM, Christensen CL, Kwiatkowski N, Kumar R, Njauw CN, Taylor M, Miao B, Zhang T, Wong KK, Gray NS, Young RA, Tsao H. High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma. *J Invest Dermatol.* 2018 Feb 2. pii: S0022-202X(18)30106-4. doi: 10.1016/j.jid.2017.09.056.
259. Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. *Cancer Cell.* 2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004.
260. Hatcher JM, Wu G, Zeng C, Zhu J, Meng F, Patel S, Wang W, Ficarro SB, Leggett AL, Powell CE, Marto JA, Zhang K, Ki Ngo JC, Fu XD, Zhang T, Gray NS. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. *Cell Chem Biol.* 2018 Feb 14. pii: S2451-9456(18)30035-7. doi: 10.1016/j.chembiol.2018.01.013.
261. Tusa I, Gagliardi S, Tubita A, Pandolfi S, Urso C, Borgognoni L, Wang J, Deng X, Gray NS, Stecca B, Rovida E. ERK5 is activated by oncogenic BRAF and promotes melanoma growth. *Oncogene.* 2018 May;37(19):2601-2614. doi: 10.1038/s41388-018-0164-9
262. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrero ML, Chan GG, Patterson CJ, Meid KE, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. BTKCys481Ser drives ibrutinib resistance via ERK1/2, and protects BTK Wild-Type MYD88 mutated cells by a paracrine mechanism. *Blood.* 2018 Mar 1
263. Giurisato E, Xu Q, Lonardi S, Telfer B, Russo I, Pearson A, Finegan KG, Wang W, Wang J, Gray NS, Vermi W, Xia Z, Tournier C. Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. *Proc Natl Acad Sci U S A.* 2018 Mar 20;115(12):E2801-E2810.
264. Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, Gray NS, Bradner JE. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. *Nat Chem Biol.* 2018 Mar 5. doi: 10.1038/s41589-018-0010-y.
265. Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong KK, Gray NS, Bradner JE. The dTAG system for immediate and target-specific protein degradation. *Nat Chem Biol.* 2018 May;14(5):431-441.
266. Bockorny B, Rusan M, Chen W, Liao RG, Li Y, Piccioni F, Wang J, Tan L, Thorner AR, Li T, Zhang Y, Miao CH, Ovesen T, Shapiro GI, Kwiatkowski DJ, Gray NS, Meyerson M, Hammerman PS, Bass AJ. RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade. *Mol Cancer Ther.* 2018 Apr 13. pii: molcanther.0464.2017. doi: 10.1158/1535-7163.MCT-17-0464.
267. Powell CE, Gao Y, Tan L, Donovan KA, Nowak RP, Loehr A, Bahcall M, Fischer ES, Janne PA, George RE, Gray NS. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). *J Med Chem.* 2018 Apr 16. doi: 10.1021/acs.jmedchem.7b01655.
268. Weir MC, Shu ST, Patel RK, Hellwig S, Chen L, Tan L, Gray NS, Smithgall TE. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. *ACS Chem Biol.* 2018 May 30. doi: 10.1021/acscchembio.8b00154.

269. Nowak RP, DeAngelo SL, Buckley D, He Z, Donovan KA, An J, Safaei N, Jedrychowski MP, Ponthier CM, Ishoey M, Zhang T, Mancias JD, Gray NS, Bradner JE, Fischer ES. Plasticity in binding confers selectivity in ligand-induced protein degradation. *Nat Chem Biol.* 2018 Jun 11. doi: 10.1038/s41589-018-0055-y.
270. de Wispelaere M, Lian W, Potisopon S, Li PC, Jang J, Ficarro SB, Clark MJ, Zhu X, Kaplan JB, Pitts JD, Wales TE, Wang J, Engen JR, Marto JA, Gray NS, Yang PL. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. *Cell Chem Biol.* 2018 Jun 1. pii: S2451-9456(18)30182-X. doi: 10.1016/j.chembiol.2018.05.011.
271. Hatcher JM, Wang ES, Johannessen L, Kwiatkowski N, Sim T, Gray NS. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. *ACS Med Chem Lett.* 2018 Mar 18;9(6):540-545. doi: 10.1021/acsmedchemlett.8b00011.
272. Jang J, Son J, Park E, Kosaka T, Saxon JA, De Clercq D, Choi HG, Tanizaki J, Eck MJ, Jänne PA, Gray NS. Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitor. *Angew Chem Int Ed Engl.* 2018 Jul 6. doi: 10.1002/anie.201805187.
273. Chao LH, Jang J, Johnson A, Nguyen A, Gray NS, Yang PL, Harrison SC. How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. *Elife.* 2018 Jul 12;7. pii: e36461. doi: 10.7554/eLife.36461.
274. Zhou W, Whiteley AT, de Oliveira Mann CC, Morehouse BR, Nowak RP, Fischer ES, Gray NS, Mekalanos JJ, Kranzusch PJ. Structure of the Human cGAS-DNA Complex Reveals Enhanced Control of Immune Surveillance. *Cell.* 2018 Jul 12;174(2):300-311.e11. doi: 10.1016/j.cell.2018.06.026.
275. Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer. *Cancer Res.* 2018 Sep 15;78(18):5203-5215.
276. Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, Durant M, Du G, Xia M, Bilchuk N, Chennamadhavuni S, Palladino G, Inghirami G, Philippar U, Wu H, Scott DA, Gray NS, Melnick A. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. *Clin Invest.* 2018 Jul 19. pii: 99436. doi: 10.1172/JCI99436.
277. Lian W, Jang J, Potisopon S, Li PC, Rahmeh A, Wang J, Kwiatkowski NP, Gray NS, Yang PL. Discovery of Immunologically Inspired Small Molecules that Target the Viral Envelope Protein. *ACS Infect Dis.* 2018 Jul 20. doi: 10.1021/acsinfectdis.8b00127.
278. Czarna A, Wang J, Zelencova D, Liu Y, Deng X, Choi HG, Zhang T, Zhou W, Chang JW, Kildalsen H, Seternes OM, Gray NS, Engh RA, Rothweiler U. Novel scaffolds for Dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A) inhibitors. *J Med Chem.* 2018 Aug 10. doi: 10.1021/acs.jmedchem.7b01847.
279. Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Masefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NS. Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazepinones as inhibitors of kinases and bromodomains. *ACS Chem Biol.* 2018 Sep 21;13(9):2438-2448.
280. Cho H, Shin I, Joo E, Choi S, Hur W, Kim H, Hong E, Kim ND, Choi HG, Gray NS, Sim T. First SAR study for overriding NRAS mutant driven acute myeloid leukemia. *J Med Chem.* 2018 Sep 27;61(18):8353-8373.
281. Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Jänne PA. A High-Throughput Immune-Oncology Screen



- Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. *Cancer Immunol Res.* 2018 Sep 21. doi: 10.1158/2326-6066.CIR-18-0193.
282. Tusa I, Cheloni G, Poteti M, Gozzini A, DeSouza NH, Shan Y, Deng X, Gray NS, Li S, Rovida E, Dello Sbarba P. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells. *Stem Cell Reports.* 2018 Oct 9;11(4):929-943.
283. Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM, Pan J, Remillard DI, Lareau CA, Zullo HJ, Fortoul N, Gray NS, Bradner JE, Chan HM, Kadoch C. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. *Nat Cell Biol.* 2018 Nov 5. doi: 10.1038/s41556-018-0221-1.
284. Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J, Shapiro GI, Liu JF, Matulonis UA, Lin CY, Konstantinopoulos PA, Gray NS. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. *Elife.* 2018 Nov 13;7. pii: e39030. doi: 10.7554/eLife.39030.
285. Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. *Elife.* 2018 Nov 15;7. pii: e41305. doi: 10.7554/eLife.41305
286. Browne CM, Jiang B, Ficarro SB, Doctor ZM, Johnson JL, Card JD, Sivakumaren SC, Alexander WM, Yaron T, Murphy CJ, Kwiatkowski NP, Zhang T, Cantley LC, Gray NS, Marto JA. A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification. *J Am Chem Soc.* 2018 Dec 06.
287. Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS. Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer. *Blood.* 2018 Dec 13
288. Brand M, Jiang B, Bauer S, Donovan KA, Liang Y, Wang ES, Nowak RP, Yuan JC, Zhang T, Kwiatkowski N, Müller AC, Fischer ES, Gray NS, Winter GE. Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. *Cell Chem Biol.* 2018 Nov 22. pii: S2451-9456(18)30413-6. doi: 10.1016/j.chembiol.2018.11.006.
289. Li PC, Jang J, Hsia CY, Grooms P, Lian W, de Wispelaere M, Pitts JD, Wang J, Kwiatkowski N, Gray NS, Yang PL. Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo. *ACS Infect Dis.* 2019 Jan 4. doi: 10.1021/acsinfectdis.8b00322.
290. Sharifnia T, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, Lawlor MA, Goodale A, Cowley GS, Vazquez F, Ott CJ, Francis JM, Sassi S, Cogswell P, Sheppard HE, Zhang T, Gray NS, Clarke PA, Blagg J, Workman P, Sommer J, Hornicek F, Root DE, Hahn WC, Bradner JE, Wong KK, Clemons PA, Lin CY, Kotz JD, Schreiber SL. Small-molecule targeting of brachyury transcription factor addiction in chordoma. *Nat Med.* 2019 Jan 21. doi: 10.1038/s41591-018-0312-3.
291. Wang L, Ferrao R, Li Q, Hatcher JM, Choi HG, Buhrlage SJ, Gray NS, Wu H. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). *J Biol Chem.* 2019 Jan 24. pii: jbc.RA118.005428. doi: 10.1074/jbc.RA118.005428.
292. Pitts J, Hsia CY, Lian W, Wang J, Pfeil MP, Kwiatkowski N, Li Z, Jang J, Gray NS, Yang PL. Identification of small molecule inhibitors targeting the Zika virus envelope protein. *Antiviral Res.* 2019 Feb 13. pii: S0166-3542(18)30765-4. doi: 10.1016/j.antiviral.2019.02.008.
293. Sung Hsieh HH, Agarwal S, Cholok DJ, Loder SJ, Kaneko K, Huber A, Chung MT, Ranganathan K, Habbouche J, Li J, Butts J, Reimer J, Kaura A, Drake J, Breuler C, Priest CR, Nguyen J, Brownley C, Peterson J, Ozgurel SU, Niknafs YS, Li S, Inagaki M, Scott G, Krebsbach P,

- Longaker MT, Westover K, Gray N, Ninomiya-Tsuji J, Mishina Y, Levi B. Coordinating Tissue Regeneration through TGF- $\beta$  Activated Kinase 1 (TAK1) In-activation and Re-activation. *Stem Cells*. 2019 Feb 20. doi: 10.1002/stem.2991.
294. Jiang B, Wang ES, Donovan KA, Liang Y, Fischer ES, Zhang T, Gray NS. Development of dual and selective degraders of cyclin-dependent kinases 4 and 6. *Angew Chem Int Ed Engl*. 2019 Feb 25. doi: 10.1002/anie.201901336.
295. Rao S, Du G, Hafner M, Subramanian K, Sorger PK, Gray NS. A multi-targeted probe-based strategy to identify signaling vulnerabilities in cancers. *J Biol Chem*. 2019 Mar 11. pii: jbc.RA118.006805. doi: 10.1074/jbc.RA118.006805.
296. Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Düster R, Geyer M, Sim T, Marto JA, Sorger PK, Westover KD, Lin CY, Kwiatkowski N, Gray NS. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. *Cell Chem Biol*. 2019 Mar 6. pii: S2451-9456(19)30067-4. doi: 10.1016/j.chembiol.2019.02.012.
297. Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D, Zhang T, Huang HT, Lucente DE, Dickerson BC, Mitchison TJ, Fischer ES, Gray NS, Haggarty SJ. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. *Elife*. 2019 Mar 25;8. pii: e45457. doi: 10.7554/eLife.45457.
298. Ferguson FM, Doctor ZM, Ficarro SB, Browne CM, Marto JA, Johnson JL, Yaron TM, Cantley LC, Kim ND, Sim T, Berberich MJ, Kalocsay M, Sorger PK, Gray NS. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. *Cell Chem Biol*. 2019 Mar 11. pii: S2451-9456(19)30070-4.
299. Hatcher JM, Du G, Fontán L, Us I, Qiao Q, Chennamadhavuni S, Shao J, Wu H, Melnick A, Gray NS, Scott DA. Peptide-based covalent inhibitors of MALT1 paracaspase. *Bioorg Med Chem Lett*. 2019 Mar 29. pii: S0960-894X(19)30199-4.
300. Moret N, Clark NA, Hafner M, Wang Y, Lounkine E, Medvedovic M, Wang J, Gray N, Jenkins J, Sorger PK. Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries. *Cell Chem Biol*. 2019 Mar 12. pii: S2451-9456(19)30073-X. doi: 10.1016/j.chembiol.2019.02.018.
301. Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Li T, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. *Cell Chem Biol*. 2019.
302. Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, Gray NS, Young RA, Geyer M, Gerber SA, George RE. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. *Nat Commun*. 2019.
303. Du L, Anderson A, Nguyen K, Ojeda SS, Ortiz-Rivera I, Nguyen TN, Zhang T, Kaoud TS, Gray NS, Dalby KN, Tsai KY. JNK2 is required for tumorigenic properties of melanoma cells. *ACS Chem Biol*. 2019 May 7. doi: 10.1021/acscchembio.9b00083.
304. Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, Koomen JM, Jiang H, Sudalagunta PR, Meads MB, Cheng F, Bi C, Fu K, Fan H, Dalton WS, Moscinski LC, Shain KH, Sotomayor EM, Wang GG, Gray NS, Cleveland JL, Qi J, Tao J. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. *Cancer Cell*. 2019 May 13;35(5):752-766.e9. doi: 10.1016/j.ccell.2019.04.005.
305. To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA.

- Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. *Cancer Discov.* 2019 Jul;9(7):926-943.
306. Scott DA, Hatcher JM, Liu H, Fu M, Du G, Fontán L, Us I, Casalena G, Qiao Q, Wu H, Melnick A, Gray NS. Quinoline and thiazolopyridine allosteric inhibitors of MALT1. *Bioorg Med Chem Lett.* 2019 Jul 15;29(14):1694-1698.
307. Ferguson FM, Doctor ZM, Ficarro SB, Marto JA, Kim ND, Sim T, Gray NS. Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. *Bioorg Med Chem Lett.* 2019 Aug 1;29(15):1985-1993. 5010.
308. Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. *Br J Haematol.* 2019 Jul 15. doi: 10.1111/bjh.16092.
309. Tang X, Drotar J, Li K, Clairmont CD, Brumm AS, Sullins AJ, Wu H, Liu XS, Wang J, Gray NS, Sur M, Jaenisch R. Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice. *Sci Transl Med.* 2019 Jul 31;11(503). pii: eaau0164. doi: 10.1126/scitranslmed.aau0164.
310. de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, Kalabathula J, Nowak RP, Fischer ES, Gray NS, Yang PL. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. *Nat Commun.* 2019 Aug 1;10(1):3468.
311. Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, Marco E, Chen T, Gray NS, Wong KK, Orkin SH, Yuan GC, Young RA, George RE. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. *Nature.* 2019 Aug;572(7771):676-680. doi: 10.1038/s41586-019-1472-0.
312. Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. *Leukemia.* 2019 Aug 27.
313. Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. *Cell Rep.* 2019 Oct 1;29(1):118-134.e8. doi: 10.1016/j.celrep.2019.08.090.
314. Remillard D, Buckley DL, Seo HS, Ferguson FM, Dhe-Paganon S, Bradner JE, Gray NS. Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. *ACS Med Chem Lett.* 2019 Sep 13;10(10):1443-1449. doi: 10.1021/acsmchemlett.9b00243.
315. Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, Edlinger L, Knab VM, Uras IZ, Grundschober E, Bauer K, Roth M, Skucha A, Liu Y, Hatcher JM, Liang Y, Kwiatkowski NP, Fux D, Hoelbl-Kovacic A, Kubicek S, Melo JV, Valent P, Weichhart T, Grebien F, Zuber J, Gray NS, Sexl V. A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. *Nat Commun.* 2019 Oct 18;10(1):4741. doi: 10.1038/s41467-019-12656-x.
316. Faust TB, Yoon H, Nowak RP, Donovan KA, Li Z, Cai Q, Eleuteri NA, Zhang T, Gray NS, Fischer ES. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. *Nat Chem Biol.* 2019 Nov 4.
317. Tarumoto Y, Lin S, Wang J, Milazzo JP, Xu Y, Lu B, Yang Z, Wei Y, Polyanskaya S, Wunderlich M, Gray NS, Stegmaier K, Vakoc CR. Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo. *Blood.* 2019 Nov 1.

318. Li Z, Pinch BJ, Olson CM, Donovan KA, Nowak RP, Mills CE, Scott DA, Doctor ZM, Eleuteri NA, Chung M, Sorger PK, Fischer ES, Gray NS. Development and Characterization of a Wee1 Kinase Degradator. *Cell Chem Biol.* 2019 Nov 13.
319. De Clercq DJH, Heppner DE, To C, Jang J, Park E, Yun CH, Mushajiang M, Shin BH, Gero TW, Scott DA, Jänne PA, Eck MJ, Gray NS. Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. *ACS Med Chem Lett.* 2019 Oct 22; 10(11):1549-1553.
320. Chopra SS, Jenney A, Palmer A, Niepel M, Chung M, Mills C, Sivakumaren SC, Liu Q, Chen JY, Yapp C, Asara JM, Gray NS, Sorger PK. Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell Syst.* 2020 Jan 22;10(1):66-81.
321. You I, Erickson EC, Donovan KA, Eleuteri NA, Fischer ES, Gray NS, Toker A. Discovery of an AKT Degradator with Prolonged Inhibition of Downstream Signaling. *Cell Chem Biol.* 2020 Jan 16;27(1):66-73.e7. doi: 10.1016/j.chembiol.2019.11.014. Epub 2019 Dec 16.
322. Zeng M, Xiong Y, Safaee N, Nowak RP, Donovan KA, Yuan CJ, Nabet B, Gero TW, Feru F, Li L, Gondi S, Ombellets LJ, Quan C, Jänne PA, Kostic M, Scott DA, Westover KD, Fischer ES, Gray NS. Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. *Cell Chem Biol.* 2020 Jan 16;27(1):19-31.e6. doi: 10.1016/j.chembiol.2019.12.006. Epub 2019 Dec 26.
323. Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, Li F, Pan Y, Zhang X, Yin Y, Papadopoulos E, Pyon V, Thakurdi C, Kwiatkowski N, Jani K, Rabin AR, Castro DM, Chen T, Silver H, Huang Q, Bulatovic M, Dowling CM, Sundberg B, Leggett A, Ranieri M, Han H, Li S, Yang A, Labbe KE, Almonte C, Sviderskiy VO, Quinn M, Donaghue J, Wang ES, Zhang T, He Z, Velcheti V, Hammerman PS, Freeman GJ, Bonneau R, Kaelin WG Jr, Sutherland KD, Kersbergen A, Aguirre AJ, Yuan GC, Rothenberg E, Miller G, Gray NS, Wong KK. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. *Cancer Cell.* 2020 Jan 13;37(1):37-54.e9. doi: 10.1016/j.ccell.2019.11.003. Epub 2019 Dec 26.
324. Kim JW, Berrios C, Kim M, Schade AE, Adelmant G, Yeerna H, Damato E, Iniguez AB, Florens L, Washburn MP, Stegmaier K, Gray NS, Tamayo P, Gjoerup O, Marto JA, DeCaprio J, Hahn WC. STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. *Elife.* 2020 Jan 8;9. pii: e53003. doi: 10.7554/eLife.53003.
325. de Wispelaere M, Carocci M, Burri DJ, Neidermyer WJ Jr, Olson CM, Roggenbach I, Liang Y, Wang J, Whelan SPJ, Gray NS, Yang PL. A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation. *J Biol Chem.* 2020 Feb 7;295(6):1694-1703. doi: 10.1074/jbc.RA119.011132. Epub 2019 Dec 30.
326. Groendyke BJ, Powell CE, Feru F, Gero TW, Li Z, Szabo H, Pang K, Feutrill J, Chen B, Li B, Gray NS, Scott DA. Benzopyrimidodiazepinone inhibitors of TNK2. *Bioorg Med Chem Lett.* 2020 Feb 15;30(4):126948. doi: 10.1016/j.bmcl.2020.126948. Epub 2020 Jan 7.
327. Du G, Rao S, Gurbani D, Henning NJ, Jiang J, Che J, Yang A, Ficarro SB, Marto JA, Aguirre AJ, Sorger PK, Westover KD, Zhang T, Gray NS. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. *J Med Chem.* 2020 Jan 30. doi: 10.1021/acs.jmedchem.9b01502.
328. Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhyay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Jänne PA. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of

- the Apoptotic Pathway. *Cancer Cell*. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006.
329. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Toure AA, Buhrlage S, Liu X, Wang J, Gray N, Stone R, Adamia S, Winer E, Sattler M, Griffin JD. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. *J Cell Mol Med*. 2020 Jan 14. doi: 10.1111/jcmm.14820.
330. Weisberg E, Meng C, Case AE, Tiv HL, Gokhale PC, Buhrlage SJ, Yang J, Liu X, Wang J, Gray N, Adamia S, Sattler M, Stone R, Griffin JD. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. *J Cell Mol Med*. 2020 Jan 22. doi: 10.1111/jcmm.14927.
331. Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrero ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. *Blood Cancer J*. 2020 Jan 31;10(1):12. doi: 10.1038/s41408-020-0277-6.
332. Yang J, Meng C, Weisberg E, Case A, Lamberto I, Magin RS, Adamia S, Wang J, Gray N, Liu S, Stone R, Sattler M, Buhrlage S, Griffin JD. Inhibition of the deubiquitinase USP10 induces degradation of SYK. *Br J Cancer*. 2020 Feb 4. doi: 10.1038/s41416-020-0731-z.
333. Hsu A, Duan Q, McMahon S, Huang Y, Wood SA, Gray NS, Wang B, Bruneau BG, Haldar SM. Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling. *J Clin Invest*. 2020 Feb 27. pii: 133753. doi: 10.1172/JCI133753.
334. Xiao H, Jedrychowski MP, Schweppe DK, Huttlin EL, Yu Q, Heppner DE, Li J, Long J, Mills EL, Szpyt J, He Z, Du G, Garrity R, Reddy A, Vaites LP, Paulo JA, Zhang T, Gray NS, Gygi SP, Chouchani ET. A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. *Cell*. 2020 Mar 5;180(5):968-983.e24. doi: 10.1016/j.cell.2020.02.012.
335. Liu J, Chen H, Ma L, He Z, Wang D, Liu Y, Lin Q, Zhang T, Gray N, Kaniskan HÜ, Jin J, Wei W. Light-induced control of protein destruction by opto-PROTAC. *Sci Adv*. 2020 Feb 21;6(8):eaay5154. doi: 10.1126/sciadv.aay5154.
336. Sivakumaren SC, Shim H, Zhang T, Ferguson FM, Lundquist MR, Browne CM, Seo HS, Paddock MN, Manz TD, Jiang B, Hao MF, Krishnan P, Wang DG, Yang TJ, Kwiatkowski NP, Ficarro SB, Cunningham JM, Marto JA, Dhe-Paganon S, Cantley LC, Gray NS. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. *Cell Chem Biol*. 2020 Mar 3. pii: S2451-9456(20)30067-2. doi: 10.1016/j.chembiol.2020.02.003.
337. Lochhead PA, Tucker JA, Tatum NJ, Wang J, Oxley D, Kidger AM, Johnson VP, Cassidy MA, Gray NS, Noble MEM, Cook SJ. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. *Nat Commun*. 2020 Mar 13;11(1):1383. doi: 10.1038/s41467-020-15031-3.
338. Manz TD, Sivakumaren SC, Yasgar A, Hall MD, Davis MI, Seo HS, Card JD, Ficarro SB, Shim H, Marto JA, Dhe-Paganon S, Sasaki AT, Boxer MB, Simeonov A, Cantley LC, Shen M, Zhang T, Ferguson FM, Gray NS. Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. *ACS Med Chem Lett*. 2019 Nov 3;11(3):346-352. doi: 10.1021/acsmchemlett.9b00402.
339. Ogino A, Choi J, Lin M, Wilkens MK, Calles A, Xu M, Adeni AE, Chambers ES, Capelletti M, Butaney M, Gray NS, Gokhale PC, Palakurthi S, Kirschmeier P, Oxnard GR, Sholl LM, Jänne PA. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. *Mol Oncol*. 2020 Mar 19. doi: 10.1002/1878-0261.12673.

340. Santana-Codina N, Chandhoke AS, Yu Q, Malachowska B, Kuljanin M, Gikandi A, Stanczak M, Gableske S, Jedrychowski MP, Scott DA, Aguirre AJ, Fendler W, Gray NS, Mancias JD. Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics. *Cell Rep.* 2020 Mar 31;30(13):4584-4599.e4. doi: 10.1016/j.celrep.2020.03.021.
341. Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, Ng RWS, Sulahian R, Li L, Poulin EJ, Huang L, Koren J, Dieguez-Martinez N, Espinosa S, Zeng Z, Corona CR, Vasta JD, Ohi R, Sim T, Kim ND, Harshbarger W, Lizcano JM, Robers MB, Muthaswamy S, Lin CY, Look AT, Haigis KM, Mancias JD, Wolpin BM, Aguirre AJ, Hahn WC, Westover KD, Gray NS. Discovery of a selective inhibitor of doublecortin like kinase 1. *Nat Chem Biol.* 2020 Apr 6. doi: 10.1038/s41589-020-0506-0.
342. Manz TD, Sivakumaren SC, Ferguson FM, Zhang T, Yasgar A, Seo HS, Ficarro SB, Card JD, Shim H, Miduturu CV, Simeonov A, Shen M, Marto JA, Dhe-Paganon S, Hall MD, Cantley LC, Gray NS. Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. *J Med Chem.* 2020 Apr 16. doi: 10.1021/acs.jmedchem.0c00227.
343. Morita K, He S, Nowak RP, Wang J, Zimmerman MW, Fu C, Durbin AD, Martel MW, Prutsch N, Gray NS, Fischer ES, Look AT. Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. *Cell.* 2020 Apr 30;181(3):702-715.
344. Gasic I, Groendyke BJ, Nowak RP, Yuan JC, Kalabathula J, Fischer ES, Gray NS, Mitchison TJ. Tubulin Resists Degradation by Cereblon-Recruiting PROTACs. *Cells.* 2020 Apr 27;9(5). pii: E1083. doi: 10.3390/cells9051083.
345. Teng M, Jiang J, He Z, Kwiatkowski NP, Donovan KA, Mills CE, Victor C, Hatcher JM, Fischer ES, Sorger PK, Zhang T, Gray NS. Development of CDK2 and CDK5 Dual Degradator TMX-2172. *Angew Chem Int Ed Engl.* 2020 Aug 10;59(33):13865-13870. doi: 10.1002/anie.202004087
346. Jaeger MG, Schwalb B, Mackowiak SD, Velychko T, Hanzl A, Imrichova H, Brand M, Agerer B, Chorn S, Nabet B, Ferguson FM, Müller AC, Bergthaler A, Gray NS, Bradner JE, Bock C, Hnisz D, Cramer P, Winter GE. Selective Mediator dependence of cell-type-specifying transcription. *Nat Genet.* 2020 Jun 1. doi: 10.1038/s41588-020-0635-0.
347. Pinch BJ, Doctor ZM, Nabet B, Browne CM, Seo HS, Mohardt ML, Kozono S, Lian X, Manz TD, Chun Y, Kibe S, Zaidman D, Daitchman D, Yeoh ZC, Vangos NE, Geffken EA, Tan L, Ficarro SB, London N, Marto JA, Buratowski S, Dhe-Paganon S, Zhou XZ, Lu KP, Gray NS. Identification of a potent and selective covalent Pin1 inhibitor. *Nat Chem Biol.* 2020 Jun 1. doi: 10.1038/s41589-020-0550-9.
348. Fan Z, Devlin JR, Hogg SJ, Doyle MA, Harrison PF, Todorovski I, Cluse LA, Knight DA, Sandow JJ, Gregory G, Fox A, Beilharz TH, Kwiatkowski N, Scott NE, Vidakovic AT, Kelly GP, Svejstrup JQ, Geyer M, Gray NS, Vervoort SJ, Johnstone RW. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. *Sci Adv.* 2020 Apr 29;6(18):eaaz5041. doi: 10.1126/sciadv.aaz5041. eCollection 2020 May. PMID: 32494677
349. Liu Y, Hao M, Leggett A, Gao Y, Ficarro SB, Che J, He Z, Olson C, Marto JA, Kwiatkowski N, Zhang T, Gray NS. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. *J Med Chem.* 2020 Jun 5. doi: 10.1021/acs.jmedchem.9b01929.
350. Gurbani D, Du G, Henning NJ, Rao S, Bera AK, Zhang T, Gray NS, Westover KD. Structure and Characterization of a Covalent Inhibitor of Src Kinase. *Front Mol Biosci.* 2020 May 19;7:81. doi: 10.3389/fmolb.2020.00081.
351. Jang J, To C, De Clercq DJH, Park E, Ponthier CM, Shin BH, Mushajiang M, Nowak RP, Fischer ES, Eck MJ, Jänne PA, Gray NS. Mutant-Selective Allosteric EGFR Degradators are Effective Against a Broad Range of Drug-Resistant Mutations. *Angew Chem Int Ed Engl.* 2020 Jun 8. doi: 10.1002/anie.202003500.

352. Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and structure activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one scaffold. *J Med Chem*. 2020 Jun 12. doi: 10.1021/acs.jmedchem.0c00596.
353. Teng M, Ficarro SB, Yoon H, Che J, Zhou J, Fischer ES, Marto JA, Zhang T, Gray NS. Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface. *ACS Med Chem Lett*. 2020 Apr 3;11(6):1269-1273. doi: 10.1021/acsmedchemlett.0c00111.
354. Klein IA, Boija A, Afeyan LK, Hawken SW, Fan M, Dall'Agnese A, Oksuz O, Henninger JE, Shrinivas K, Sabari BR, Sagi I, Clark VE, Platt JM, Kar M, McCall PM, Zamudio AV, Manteiga JC, Coffey EL, Li CH, Hannett NM, Guo YE, Decker TM, Lee TI, Zhang T, Weng JK, Taatjes DJ, Chakraborty A, Sharp PA, Chang YT, Hyman AA, Gray NS, Young RA. Partitioning of cancer therapeutics in nuclear condensates. *Science*. 2020 Jun 19;368(6497):1386-1392. doi: 10.1126/science.aaz4427.
355. Giurisato E, Lonardi S, Telfer B, Lussoso S, Risa-Ebrí B, Zhang J, Russo I, Wang J, Santucci A, Finegan KG, Gray NS, Vermi W, Tournier C. Extracellular-regulated protein kinase 5-mediated control of p21 expression promotes macrophage proliferation associated with tumor growth and metastasis. *Cancer Res*. 2020 Jun 19;canres.2416.2019. doi: 10.1158/0008-5472.CAN-19-2416.
356. Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, Feit AS, Bergholz J, Michowski W, Otto T, Sheng Q, Loo A, Michael W, Tiedt R, DeAngelis C, Schiff R, Jiang B, Jovanovic B, Nowak K, Ericsson M, Cameron M, Gray N, Dillon D, Zhao JJ, Sabatini DM, Jeselsohn R, Brown M, Polyak K, Sicinski P. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. *Sci Adv*. 2020 Jun 17;6(25):eabb2210. doi: 10.1126/sciadv.abb2210. eCollection 2020 Jun. PMID: 32704543
357. Li Z, Powell CE, Groendyke BJ, Gero TW, Feru F, Feutrill J, Chen B, Li B, Szabo H, Gray NS, Scott DA. Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing. *Bioorg Med Chem Lett*. 2020 Oct 1;30(19):127456.
358. Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell Chem Biol*. 2020 Oct 15;27(10):1229-1240.e4.
359. Schröder M, Tan L, Wang J, Liang Y, Gray NS, Knapp S, Chaikuad A. Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. *Cell Chem Biol*. 2020 Oct 15;27(10):1285-1295.e4.
360. Powell CE, Du G, Che J, He Z, Donovan KA, Yue H, Wang ES, Nowak RP, Zhang T, Fischer ES, Gray NS. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library. *ACS Chem Biol*. 2020 Oct 16;15(10):2722-2730.
361. Jiang J, Jiang B, He Z, Ficarro SB, Che J, Marto JA, Gao Y, Zhang T, Gray NS. Discovery of Covalent MKK4/7 Dual Inhibitor. *Cell Chem Biol*. 2020 Sep 7:S2451-9456(20)30336-6.
362. Fan Z, Devlin JR, Hogg SJ, Doyle MA, Harrison PF, Todorovski I, Cluse LA, Knight DA, Sandow JJ, Gregory G, Fox A, Beilharz TH, Kwiatkowski N, Scott NE, Vidakovic AT, Kelly GP, Svejstrup JQ, Geyer M, Gray NS, Vervoort SJ, Johnstone RW. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. *Sci Adv*. 2020 Apr 29;6(18):eaaz5041.
363. Nabet B, Ferguson FM, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, Robichaud A, Conway AS, Buckley DL, Mancias JD, Bradner JE, Stegmaier K, Gray NS. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. *Nat Commun*. 2020 Sep 18;11(1):4687.
364. Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, Barker K, Urban Z, Thway K, Zeid R, Hallsworth A, Box G, Ebus ME, Licciardello MP, Sbirkov Y, Lazaro G, Calton E, Costa BM,

- Valenti M, De Haven Brandon A, Webber H, Tardif N, Almeida GS, Christova R, Boysen G, Richards MW, Barone G, Ford A, Bayliss R, Clarke PA, De Bono J, Gray NS, Blagg J, Robinson SP, Eccles SA, Zheleva D, Bradner JE, Molenaar J, Vivanco I, Eilers M, Workman P, Lin CY, Chesler L. Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. *J Clin Invest*. 2020 Oct 5;134:132. doi: 10.1172/JCI134132.
365. Hatcher JM, Yang G, Wang L, Ficarro SB, Buhrlage S, Wu H, Marto JA, Treon SP, Gray NS. Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. *ACS Med Chem Lett*. 2020 Oct 9;11(11):2238-2243. doi: 10.1021/acsmchemlett.0c00378.
366. Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, Teng M, Liang Y, Hatcher J, Li Z, Manz TD, Groendyke B, Hu W, Nam Y, Sengupta S, Cho H, Shin I, Agius MP, Ghobrial IM, Ma MW, Che J, Buhrlage SJ, Sim T, Gray NS, Fischer ES. Mapping the Degradable Kinome Provides a Resource for Expedited Degradation Development. *Cell*. 2020 Dec 10;183(6):1714-1731.e10. doi: 10.1016/j.cell.2020.10.038.
367. Shirasaki R, Matthews GM, Gandolfi S, de Matos Simoes R, Buckley DL, Raja Vora J, Sievers QL, Brüggenthies JB, Dashevsky O, Poarch H, Tang H, Bariteau MA, Sheffer M, Hu Y, Downey-Kopyscinski SL, Hengeveld PJ, Glassner BJ, Dhimolea E, Ott CJ, Zhang T, Kwiatkowski NP, Laubach JP, Schlossman RL, Richardson PG, Culhane AC, Groen RWJ, Fischer ES, Vazquez F, Tsherniak A, Hahn WC, Levy J, Auclair D, Licht JD, Keats JJ, Boise LH, Ebert BL, Bradner JE, Gray NS, Mitsiades CS. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradation of Oncoproteins. *Cell Rep*. 2021 Jan 5;34(1):108532. doi: 10.1016/j.celrep.2020.108532. PMID: 33406420
368. Levine ZG, Potter SC, Joiner CM, Fei GQ, Nabet B, Sonnett M, Zachara NE, Gray NS, Paulo JA, Walker S. Mammalian cell proliferation requires noncatalytic functions of O-GlcNAc transferase. *Proc Natl Acad Sci U S A*. 2021 Jan 26;118(4):e2016778118. doi: 10.1073/pnas.2016778118. PMID: 33419956 Free article.
369. Dhimolea E, de Matos Simoes R, Kansara D, Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, Tang H, Glassner BJ, Liu Z, Gao D, Bryan J, Bender S, Roth J, Scheffer M, Jeselsohn R, Gray NS, Georgakoudi I, Vazquez F, Tsherniak A, Chen Y, Welm A, Duy C, Melnick A, Bartholdy B, Brown M, Culhane AC, Mitsiades CS. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. *Cancer Cell*. 2021 Jan 5;S1535-6108(20)30609-7. doi: 10.1016/j.ccell.2020.12.002.
370. Wells CI, Al-Ali H, Andrews DM, Asquith CRM, Axtman AD, Dikic I, Ebner D, Etmayer P, Fischer C, Frederiksen M, Futrell RE, Gray NS, Hatch SB, Knapp S, Lücking U, Michaelides M, Mills CE, Müller S, Owen D, Picado A, Saikatendu KS, Schröder M, Stolz A, Tellechea M, Turunen BJ, Vilar S, Wang J, Zuercher WJ, Willson TM, Drewry DH. The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. *Int J Mol Sci*. 2021 Jan 8;22(2):E566. doi: 10.3390/ijms22020566.
371. Groendyke BJ, Nabet B, Mohardt ML, Zhang H, Peng K, Koide E, Coffey CR, Che J, Scott DA, Bass AJ, Gray NS. Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor. *ACS Med Chem Lett*. 2020 Dec 14;12(1):30-38. doi: 10.1021/acsmchemlett.0c00338.
372. Sheppard HE, Dall'Agnesse A, Park WD, Shamim MH, Dubrulle J, Johnson HL, Stossi F, Cogswell P, Sommer J, Levy J, Sharifnia T, Wawer MJ, Nabet B, Gray NS, Clemons PA, Schreiber SL, Workman P, Young RA, Lin CY. Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. *Cell Rep Med*. 2021 Jan 19;2(1):100188. doi: 10.1016/j.xcrm.2020.100188.



373. Koduri V, Duplaquet L, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, Ott CJ, Zhang T, Donovan KA, Fischer ES, Gygi SP, Gray NS, Bradner J, Medin JA, Buhrlage SJ, Oser MG, Kaelin WG Jr. Targeting oncoproteins with a positive selection assay for protein degraders. *Sci Adv.* 2021 Feb 5;7(6):eabd6263. doi: 10.1126/sciadv.abd6263.
374. Jiang B, Gao Y, Che J, Lu W, Kaltheuner IH, Dries R, Kalocsay M, Berberich MJ, Jiang J, You I, Kwiatkowski N, Riching KM, Daniels DL, Sorger PK, Geyer M, Zhang T, Gray NS. Discovery and resistance mechanism of a selective CDK12 degrader. *Nat Chem Biol.* 2021 Mar 22. doi: 10.1038/s41589-021-00765-y.
375. Du G, Jiang J, Wu Q, Henning NJ, Donovan KA, Yue H, Che J, Lu W, Fischer ES, Bardeesy N, Zhang T, Gray NS. Discovery of a Potent Degradator for Fibroblast Growth Factor Receptor 1/2. *Angew Chem Int Ed Engl.* 2021 Apr 29. doi: 10.1002/anie.202101328. Online ahead of print. PMID: 33915015
376. Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, Roehle K, Luoma A, Boelaars K, Peters V, McCreary J, Boschert T, Wang ES, Suo S, Marangoni F, Mempel TR, Long HW, Wucherpfennig KW, Dougan M, Gray NS, Yuan GC, Goel S, Tolaney SM, Dougan SK. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. *Cancer Discov.* 2021 May 3:candisc.1540.2020. doi: 10.1158/2159-8290.
377. Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, Gray NS. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. *Eur J Med Chem.* 2021 Apr 20;221:113481. doi: 10.1016/j.ejmech.2021.113481.
378. Dubiella C, Pinch BJ, Koikawa K, Zaidman D, Poon E, Manz TD, Nabet B, He S, Resnick E, Rogel A, Langer EM, Daniel CJ, Seo HS, Chen Y, Adelmant G, Sharifzadeh S, Ficarro SB, Jamin Y, Martins da Costa B, Zimmerman MW, Lian X, Kibe S, Kozono S, Doctor ZM, Browne CM, Yang A, Stoler-Barak L, Shah RB, Vangos NE, Geffken EA, Oren R, Koide E, Sidi S, Shulman Z, Wang C, Marto JA, Dhe-Paganon S, Look T, Zhou XZ, Lu KP, Sears RC, Chesler L, Gray NS, London N. Sulfofin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. *Nat Chem Biol.* 2021 May 10. doi: 10.1038/s41589-021-00786-7.
379. Remenyi J, Naik RJ, Wang J, Razsolkov M, Verano A, Cai Q, Tan L, Toth R, Raggett S, Baillie C, Traynor R, Hastie CJ, Gray NS, Arthur JSC. Generation of a chemical genetic model for JAK3. *Sci Rep.* 2021 May 12;11(1):10093. doi: 10.1038/s41598-021-89356-4.
380. Carli ALE, Afshar-Sterle S, Rai A, Fang H, O'Keefe R, Tse J, Ferguson FM, Gray NS, Ernst M, Greening DW, Buchert M. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. *Proteomics.* 2021 May 15:e2000098. doi: 10.1002/pmic.202000098.
381. Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. *Cell.* 2021 May 12:S0092-8674(21)00502-X. doi: 10.1016/j.cell.2021.04.022.
382. Wang ES, Verano AL, Nowak RP, Yuan JC, Donovan KA, Eleuteri NA, Yue H, Ngo KH, Lizotte PH, Gokhale PC, Gray NS, Fischer ES. Acute pharmacological degradation of Helios destabilizes regulatory T cells. *Nat Chem Biol.* 2021 Jun;17(6):711-717.

383. Arnett A, Moo KG, Flynn KJ, Sundberg TB, Johannessen L, Shamji AF, Gray NS, Decker T, Zheng Y, Gersuk VH, Rahman ZS, Levy DE, Marié IJ, Linsley PS, Xavier RJ, Khor B. The CDK8 inhibitor DCA promotes a tolerogenic chemical immunophenotype in CD4<sup>+</sup> T cells via a novel CDK8-GATA3-FOXP3 pathway. *Mol Cell Biol*. 2021 Jun 14: MCB0008521. doi: 10.1128/MCB.00085-21.
384. Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos M, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid KE, Castillo J, Munshi NC, Anderson KC, Cameron M, Buhrlage S, Gray NSS, Treon SPP. The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. *Blood*. 2021 Jun 16: blood.2021011405. doi: 10.1182/blood.2021011405.
385. Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, Poirier JT, Peng D, Bulatovic M, Mukhopadhyay S, Silver H, Papadopoulos E, Pyon V, Thakurdin C, Han H, Li F, Li S, Ding H, Hu H, Pan Y, Weerasekara V, Jiang B, Wang ES, Ahearn I, Philips M, Papagiannakopoulos T, Tsirigos A, Rothenberg E, Gainor J, Freeman GJ, Rudin CM, Gray NS, Hammerman PS, Pagano M, Heymach JV, Perou CM, Bardeesy N, Wong KK. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. *Nat Cancer*. 2021 May;2(5):503-514. doi: 10.1038/s43018-021-00208-6.
386. Tang CC, Castro Andrade CD, O'Meara MJ, Yoon SH, Sato T, Brooks DJ, Bouxsein ML, Martins JDS, Wang J, Gray NS, Misof B, Roschger P, Boulin S, Klaushofer K, Velduis-Vlug A, Vegting Y, Rosen CJ, O'Connell D, Sundberg TB, Xavier RJ, Ung P, Schlessinger A, Kronenberg HM, Berdeaux R, Foretz M, Wein MN. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. *Elife*. 2021 Jun 23;10:e67772. doi: 10.7554/eLife.67772.
387. Seong BKA, Dharia NV, Lin S, Donovan KA, Chong S, Robichaud A, Conway A, Hamze A, Ross L, Alexe G, Adane B, Nabet B, Ferguson FM, Stolte B, Wang EJ, Sun J, Darzacq X, Piccioni F, Gray NS, Fischer ES, Stegmaier K. TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. *Cancer Cell*. 2021 Jul 22:S1535-6108(21)00380-9. doi: 10.1016/j.ccell.2021.07.003.
388. Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, Nezu Y, Ke S, Qiu C, Ohuchida K, Oda Y, Lee TH, Wegiel B, Clohessy JG, London N, Santagata S, Wulf GM, Hidalgo M, Muthuswamy SK, Nakamura M, Gray NS, Zhou XZ, Lu KP. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. *Cell*. 2021 Aug 6:S0092-8674(21)00879-5. doi: 10.1016/j.cell.2021.07.020.
389. Teng M, Jiang J, Ficarro SB, Seo HS, Bae JH, Donovan KA, Fischer ES, Zhang T, Dhe-Paganon S, Marto JA, Gray NS. Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degradation Development. *ACS Med Chem Lett*. 2021 Jul 21;12(8):1302-1307. doi: 10.1021/acsmchemlett.1c00285.
390. Powell CE, Du G, Bushman JW, He Z, Zhang T, Fischer ES, Gray NS. Selective degradation-inducing probes for studying cereblon (CRBN) biology. *RSC Med Chem*. 2021 Jul 6;12(8):1381-1390. doi: 10.1039/d0md00382d.

### Other Peer-Reviewed Publications

1. **Gray NS**, Detivaud L, Doerig C, Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. *Curr Med Chem* 1999;6:859-75.
2. **Gray NS**. Combinatorial libraries and biological discovery. *Curr Opin Neurobiol* 2001;11:608-14.
3. Ruetz S, Fabbro D, Zimmermann J, Meyer T, **Gray N**. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors. *Curr Med Chem Anticancer Agents* 2003;3:1-14.

4. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, **Gray N**. SRC family kinases: potential targets for the treatment of human cancer and leukemia. *Curr Pharm Des* 2003;9:2043-59.
5. Li B, Liu Y, Uno T, **Gray N**. Creating chemical diversity to target protein kinases. *Comb Chem High Throughput Screen* 2004;7:453-72.
6. Nagle A, Hur W, **Gray NS**. Antimitotic agents of natural origin. *Curr Drug Targets* 2006;7:305-26.
7. Liu Y, **Gray NS**. Rational design of inhibitors that bind to inactive kinase conformations. *Nat Chem Biol* 2006;2:358-64.
8. Peters EC, **Gray NS**. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. *ACS Chem Biol* 2007;2(10):661-4.
9. Goldstein DM, **Gray NS**, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. *Nat Rev Drug Discov* 2008;7(5):391-7.
10. Zhang J, Yang PL, **Gray NS**. Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer* 2009;9(1):28-39.
11. Weisberg E, Barrett R, Liu Q, Stone R, **Gray N**, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. *Drug Resist Updat* 2009;12(3):81-9.
12. Jänne PA, **Gray NS**, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. *Nat Rev Drug Discov*. 2009 Sep;8(9):709-23.
13. Liu Q, Thoreen C, Wang J, Sabatini D, **Gray NS**. mTOR Mediated Anti-Cancer Drug Discovery. *Drug Discov Today Ther Strateg*. 2009 Summer;6(2):47-55. PMID:20622997
14. Hur W, **Gray NS**. Small molecule modulators of antioxidant response pathway. *Curr Opin Chem Biol*. 2011 Feb;15(1):162-73. Epub 2010 Dec 30. Review. PMID:21195017
15. Haber DA, **Gray NS**, Baselga J. The evolving war on cancer. *Cell*. 2011 Apr 1;145(1):19-24. PMID:21458664
16. Deng X, **Gray NS**. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756). *Expert Opin Ther Pat*. 2012 Jun;22(6):709-13
17. Deng X, Choi HG, Buhrlage SJ, **Gray NS**. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). *Expert Opin Ther Pat*. 2012 Dec;22(12):1415-26.
18. Knapp S, Arruda P, Blagg J, Burley S, Drewry DH, Edwards A, Fabbro D, Gillespie P, Gray NS, Kuster B, Lackey KE, Mazzafera P, Tomkinson NC, Willson TM, Workman P, Zuercher WJ. A public-private partnership to unlock the untargeted kinome. *Nat Chem Biol*. 2013 Jan;9(1):3-6.
19. Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. Developing irreversible inhibitors of the protein kinase cysteinome. *Chem Biol*. 2013 Feb 21;20(2):146-59.
20. Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of Type II Binding Mode: a Privileged Approach for Kinase Inhibitor Focused Drug Discovery? *ACS Chem Biol*. 2014 Apr 14.
21. Wang J, Gray NS. SnapShot: Kinase Inhibitors I. *Mol Cell*. 2015 May 21;58(4):708-708.
22. Wang J, Gray NS. SnapShot: Kinase Inhibitors II. *Mol Cell*. 2015 May 21;58(4):710-710.
23. Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ. The promise and peril of chemical probes. *Nat Chem Biol*. 2015 Jul 21;11(8):536-41.
24. Müller S, Chaikuad A, Gray NS, Knapp S. The ins and outs of selective kinase inhibitor development. *Nat Chem Biol*. 2015 Oct 20;11(11):818-21.
25. Westover KD, Jänne PA, Gray NS. Progress on Covalent Inhibition of KRASG12C. *Cancer Discov*. 2016 Mar;6(3):233-4.

26. Keenan AB, Jenkins SL, Jagodnik KM, Koplev S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A, Kuleshov MV, Ma'ayan A, Stathias V, Terryn R, Cooper D, Forlin M, Koleti A, Vidovic D, Chung C, Schürer SC, Vasiliauskas J, Pilarczyk M, Shamsaei B, Fazel M, Ren Y, Niu W, Clark NA, White S, Mahi N, Zhang L, Kouril M, Reichard JF, Sivaganesan S, Medvedovic M, Meller J, Koch RJ, Birtwistle MR, Iyengar R, Sobie EA, Azeloglu EU, Kaye J, Osterloh J, Haston K, Kalra J, Finkbiener S, Li J, Milani P, Adam M, Escalante-Chong R, Sachs K, Lenail A, Ramamoorthy D, Fraenkel E, Daigle G, Hussain U, Coye A, Rothstein J, Sareen D, Ornelas L, Banuelos M, Mandefro B, Ho R, Svendsen CN, Lim RG, Stocksdale J, Casale MS, Thompson TG, Wu J, Thompson LM, Dardov V, Venkatraman V, Matlock A, Van Eyk JE, Jaffe JD, Papanastasiou M, Subramanian A, Golub TR, Erickson SD, Fallahi-Sichani M, Hafner M, Gray NS, Lin JR, Mills CE, Muhlich JL, Niepel M, Shamu CE, Williams EH, Wrobel D, Sorger PK, Heiser LM, Gray JW, Korkola JE, Mills GB, LaBarge M, Feiler HS, Dane MA, Bucher E, Nederlof M, Sudar D, Gross S, Kilburn DF, Smith R, Devlin K, Margolis R, Derr L, Lee A, Pillai A. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. *Cell Syst.* 2017 Nov 24. pii: S2405-4712(17)30490-8. doi: 10.1016/j.cels.2017.11.001.
27. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. *Nat Rev Drug Discov.* 2018 Mar 16. doi: 10.1038/nrd.2018.21.
28. Nabet B, Gray NS. It Takes Two To Target: A Study in KRAS Dimerization. *Biochemistry.* 2018 Apr 12.
29. Rodon Ahnert J, Gray N, Mok T, Gainor J. What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule. *Am Soc Clin Oncol Educ Book.* 2019 Jan;39:196-205.
30. Zhang T, Hatcher JM, Teng M, Gray NS, Kostic M. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. *Cell Chem Biol.* 2019 Oct 16.
31. Weisberg E, Sattler M, Yang PL, Parent A, Gray N, Griffin JD. Current Therapies Under Investigation for COVID-19. *Can J Physiol Pharmacol.* 2020 Jul 8. doi: 10.1139/cjpp-2020-0286.
32. Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. *Pharm Res.* 2020 Aug 10;37(9):167.